<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004056" GROUP_ID="SKIN" ID="566100061312323754" MERGED_FROM="" MODIFIED="2015-10-07 11:39:06 +0100" MODIFIED_BY="Helen Scott" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;13 Nov 02 Uta added some co-reviewers email addresses, corrected minor spelling mistakes.&lt;/p&gt;&lt;p&gt;form Gudula, 17 apr 02 - version sent to LN to decide if ready peer review&lt;/p&gt;&lt;p&gt;25apr02, LN says ready for peer review but HW and I want some changes made&lt;/p&gt;&lt;p&gt;21 May 02, Jay has started text edits:&lt;br&gt;Carried out Tina's and Hywel's text edits&lt;br&gt;Put in extra headings under search strategy &amp;amp; methods of review and apportioned text &lt;br&gt;Added headings to method quality section&lt;br&gt;Added missing dates to all reference IDs in text and sorted out 'odd looking' ref IDs in text. Did not check the actual references though&lt;/p&gt;&lt;p&gt;29may02 :TL has added data table, started moving refs to ecxluded studies, started excluded studies table, edited search strategy section&lt;/p&gt;&lt;p&gt;30 May 02: JC continuing TL's text edits&lt;/p&gt;&lt;p&gt;6june02: TL and SH have worked further on text and data tables &lt;/p&gt;&lt;p&gt;still needs:&lt;/p&gt;&lt;p&gt;cover sheet: fill in reviewers citation&lt;/p&gt;&lt;p&gt;synopsis: to be written&lt;/p&gt;&lt;p&gt;text: check our changes and respond to **NOTES&lt;/p&gt;&lt;p&gt;Methodological quality of included studies - this section needs a lot more&lt;/p&gt;&lt;p&gt;Tables: the excluded studies table was empty - I have started filling in the data for you -check what I have done and complete the table&lt;/p&gt;&lt;p&gt;included studies table - some of this was incorrect - see NOTES&lt;/p&gt;&lt;p&gt;comparisons and data table - there was no data entered - we have done it for you - please check that it is OK including the headings&lt;/p&gt;&lt;p&gt;Adverse effects: we have moved the data to a comparisons and data 'other' table - please check and tell us what 'yes' signifies&lt;/p&gt;&lt;p&gt;refs: remove studies from pending that are NOT pending&lt;/p&gt;&lt;p&gt;12 sept 02, rec'd from Gudula - ready for peer review? yes!&lt;/p&gt;&lt;p&gt; 7.11.02 - rec'd from Gudula after responding to peer review comments - she has checked the review again for typing errors, from her point of view it is ready&lt;br&gt;for re-submission. Sarah Garner has been helping her to finish the revisions.&lt;/p&gt;&lt;p&gt;13nov02 - Uta has done HW's copyedits&lt;/p&gt;&lt;p&gt;14nov02 - more edits by TL&lt;/p&gt;&lt;p&gt;15nov02 - more edits by TL&lt;/p&gt;&lt;p&gt;18 nov02 - final edits?&lt;/p&gt;&lt;p&gt;submitted to CLIB with change of unit from ml to micro litre&lt;/p&gt;&lt;p&gt;28 nov02 - few more small edits from Gudula for next submission&lt;/p&gt;&lt;p&gt;17june03 - pasted in revised synopsis from Hilda after agreement from Gudula&lt;/p&gt;&lt;p&gt;210ct04 - assigned same issue number to 'protocol fist published' as for review following advice from Rasmus /EMAG&lt;br&gt; 'In case you have any reviews for which a protocol was never published either because the review 'overtook' the protocol or a protocol was never prepared separately, we suggest that you assign the same issue number to 'Protocols first published' as to 'Review first published' instead of leaving it blank.'&lt;/p&gt;&lt;p&gt;20june05 - sent to Gudula for updating&lt;/p&gt;&lt;p&gt;12 july 05 - o.k. from NK regarding up-date; up-date sent to Tina&lt;/p&gt;&lt;p&gt;10.10.2005 uo-date 2005; okayed from NK sent to Tina&lt;/p&gt;&lt;p&gt;have received comments of 2 internal reviewers from Tina on 11.01.2006&lt;/p&gt;&lt;p&gt;revision of review by GK 24.01.2006&lt;br&gt;review and comments sent back to Tina and NK&lt;/p&gt;&lt;p&gt;31.03.06 GK used the by Philippa revised version (addition of tables) to finalize the up-date of the review&lt;br&gt;still some doubt about how the review should be updated in the future.&lt;/p&gt;&lt;p&gt;Sent back to Helen on 31.03.2006&lt;/p&gt;&lt;p&gt;03 May 06 - Edited and sent to Wiley for copyedit support (HLN)&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-10-07 11:37:24 +0100" NOTES_MODIFIED_BY="Helen Scott" REVIEW_NO="#22" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2015-10-07 11:39:06 +0100" MODIFIED_BY="Helen Scott">
<TITLE>Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita</TITLE>
<CONTACT MODIFIED="2015-10-07 11:39:06 +0100" MODIFIED_BY="Helen Scott"><PERSON ID="16372" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Gudula</FIRST_NAME><LAST_NAME>Kirtschig</LAST_NAME><POSITION>Dermatologist</POSITION><EMAIL_1>g.kirtschig@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Institute of General Medicine and Interprofessional Care</DEPARTMENT><ORGANISATION>University of Tübingen</ORGANISATION><CITY>Tübingen</CITY><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>0049-7071 36 59 700</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-10-07 11:39:06 +0100" MODIFIED_BY="Helen Scott"><PERSON ID="16372" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Gudula</FIRST_NAME><LAST_NAME>Kirtschig</LAST_NAME><POSITION>Dermatologist</POSITION><EMAIL_1>g.kirtschig@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Institute of General Medicine and Interprofessional Care</DEPARTMENT><ORGANISATION>University of Tübingen</ORGANISATION><CITY>Tübingen</CITY><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>0049-7071 36 59 700</PHONE_1></ADDRESS></PERSON><PERSON ID="16382" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Dedee</FIRST_NAME><MIDDLE_INITIALS>F</MIDDLE_INITIALS><LAST_NAME>Murrell</LAST_NAME><POSITION>Professor of Dermatology</POSITION><EMAIL_1>D.Murrell@unsw.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Dermatology</DEPARTMENT><ORGANISATION>St George Hospital &amp; University of New South Wales</ORGANISATION><ADDRESS_1>Belgrave St</ADDRESS_1><ADDRESS_2>Kogarah</ADDRESS_2><CITY>Sydney</CITY><ZIP>2217</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 29 350 2543</PHONE_1><FAX_1>+61 29 350 29906</FAX_1></ADDRESS></PERSON><PERSON ID="16426" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Fenella</FIRST_NAME><LAST_NAME>Wojnarowska</LAST_NAME><EMAIL_1>fenella@northtregeare.com</EMAIL_1><ADDRESS><DEPARTMENT>Nuffield Department of Clinical Medicine</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><CITY>Oxford</CITY><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="16371" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Nonhlanhla</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Khumalo</LAST_NAME><POSITION>Dermatologist</POSITION><EMAIL_1>n.khumalo@uct.ac.za</EMAIL_1><ADDRESS><DEPARTMENT>Department of Dermatology</DEPARTMENT><ORGANISATION>Groote Schuur Hospital</ORGANISATION><ADDRESS_1>Anzio Road</ADDRESS_1><ADDRESS_2>Observatory</ADDRESS_2><CITY>Cape Town</CITY><ZIP>7925</ZIP><REGION>Western Cape</REGION><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 21 4049 111 ext: 3376</PHONE_1><FAX_1>+27 21 4478 232</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-06-17 13:59:19 +0100" MODIFIED_BY="Cathy Bennett">
<UP_TO_DATE>
<DATE DAY="24" MONTH="1" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="4" YEAR="2005"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="7" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2003"/>
</DATES>
<WHATS_NEW MODIFIED="2015-10-07 11:37:24 +0100" MODIFIED_BY="Helen Scott" NOTES="&lt;p&gt;No new RCTs were found for the treatment of MMP and EBA.&lt;br&gt;Besides many case reports and small case series, there were three uncontrolled and one controlled study for the treatment of MMP with groups of 14 to 22 participants. However, the diagnosis of MMP was reported to be confirmed by immunofluorescence tests in only two studies. Interventions in the four studies were intravenous immuoglobulins, methotrexate, mycophenolate mofetil, and very potent topical steroids (clobetasol propionate) applied using custom trays. &lt;br&gt;&lt;br&gt;Results of the one prospective trial for the treatment of EBA by Gordon could not be obtained (not published?; investigator did not respond)&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-10-07 11:37:24 +0100" NOTES_MODIFIED_BY="Helen Scott">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-10-07 11:37:24 +0100" MODIFIED_BY="Helen Scott">
<DATE DAY="7" MONTH="10" YEAR="2015"/>
<DESCRIPTION>
<P>Author information (affiliation) updated (Gudula Kirtschig)</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-10-07 11:36:33 +0100" MODIFIED_BY="Helen Scott">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-10-07 11:36:31 +0100" MODIFIED_BY="Helen Scott">
<DATE DAY="31" MONTH="3" YEAR="2015"/>
<DESCRIPTION>
<P>Fenella and Dedee's affiliations have been slightly amended.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2015-10-07 11:36:33 +0100" MODIFIED_BY="Helen Scott">
<DATE DAY="14" MONTH="5" YEAR="2014"/>
<DESCRIPTION>
<P>The conclusion is so certain that the addition of new information will not change it, and there is unlikely to be any more research done on this topic. There were no ongoing studies or studies awaiting classification listed in the last published review, and a search of MEDLINE and Embase in 2014 found no recent results.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-02-20 11:15:23 +0000" MODIFIED_BY="Laura E Prescott">
<DATE DAY="17" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="24" MONTH="1" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-06-17 13:59:33 +0100" MODIFIED_BY="Cathy Bennett">
<DATE DAY="31" MONTH="3" YEAR="2005"/>
<DESCRIPTION>
<P>New studies sought but none found</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-06-17 13:59:38 +0100" MODIFIED_BY="Cathy Bennett">
<DATE DAY="16" MONTH="6" YEAR="2003"/>
<DESCRIPTION>
<P>Minor update</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Nuffield Trust Fellowship Scheme</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-02-20 11:17:12 +0000" MODIFIED_BY="Laura E Prescott">
<SUMMARY MODIFIED="2008-06-17 14:01:46 +0100" MODIFIED_BY="Cathy Bennett" NOTES="&lt;p&gt;New plain language title added&lt;/p&gt;" NOTES_MODIFIED="2008-06-17 14:01:46 +0100" NOTES_MODIFIED_BY="Cathy Bennett">
<TITLE MODIFIED="2008-06-17 14:01:24 +0100" MODIFIED_BY="Cathy Bennett" NOTES="&lt;p&gt;New plain language title added&lt;/p&gt;" NOTES_MODIFIED="2008-06-17 14:01:24 +0100" NOTES_MODIFIED_BY="Cathy Bennett">Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita (rare autoimmune blistering diseases of the skin, eyes and mouth)</TITLE>
<SUMMARY_BODY MODIFIED="2008-06-17 14:00:06 +0100" MODIFIED_BY="Cathy Bennett">
<P>Mucous membrane pemphigoid and epidermolysis bullosa acquisita are rare autoimmune blistering diseases of the skin and mucous membranes (eyes and mouth). They can result in scarring, which may lead to disabling and life threatening complications. Treatments include corticosteroids, mycophenolate mofetil and cyclophosphamide to suppress the immune system, and less toxic drugs such as antibiotics. These diseases often progress despite treatment. There is some evidence that mucous membrane pemphigoid involving the eyes may respond better to treatment with cyclophosphamide combined with corticosteroids, compared to treatment with corticosteroids alone. Cyclophosphamide is, however, associated with potentially severe adverse effects. Dapsone may help moderate disease. More research is needed to identify the most effective treatment options.There is not enough reliable evidence about treatments for the rare blistering diseases, mucous membrane pemphigoid and epidermolysis bullosa acquisita.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-06-18 09:38:22 +0100" MODIFIED_BY="Diane A  Horsley">
<ABS_BACKGROUND>
<P>Mucous membrane pemphigoid and epidermolysis bullosa acquisita are rare acquired autoimmune blistering diseases of the skin. Both can result in scarring of mucous membranes which may lead to blindness and life threatening respiratory complications.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effects of treatments for mucous membrane pemphigoid and epidermolysis bullosa acquisita.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Skin Group Specialised Register (7th April 2005), the Cochrane Controlled Trials Register (<I>The Cochrane Library </I>Issue 1, 2005), MEDLINE / PubMed (from 1966 to April 2005), EMBASE (from 1980 to April 2005), www.controlled-trials.com (7th April 2005) and www.clinicaltrials.gov (7th April 2005) and reference lists of articles. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials of any treatments for mucous membrane pemphigoid or epidermolysis bullosa acquisita involving participants of any age with a diagnosis of either disease confirmed by immunofluorescence.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>The data was independently extracted by three authors and subsequently checked for discrepancies. Two authors evaluated the studies in terms of the inclusion criteria.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-06-18 09:38:22 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Two small randomised controlled trials of mucous membrane pemphigoid, both conducted in participants with severe eye involvement were identified.</P>
<P>In the first trial, involving 24 participants, cyclophosphamide 2 mg/kg/day in combination with prednisone starting at 1 mg/kg/day and tapering was superior to prednisone alone (1 mg/kg/day) after 6 months of treatment. All 12 participants responded well to cyclophosphamide plus prednisone versus a good response in only 5 of 12 participants treated with prednisone (relative risk 2.40, 95% confidence interval 1.23 to 4.69).</P>
<P>In the second trial, involving 40 participants, all 20 participants treated with cyclophosphamide (2 mg/kg/day) responded well after three months of treatment, but only 14 of 20 participants responded to treatment with dapsone (2 mg/kg/day) (relative risk 1.43, 95% confidence interval 1.07 to 1.90). All non-responders had severe inflammatory activity. It was not explicitly stated whether these participants received prednisone in addition to dapsone or cyclophosphamide initially. Hair loss and suppression of the red and white blood cells were common adverse events in the cyclophosphamide groups.</P>
<P>No randomised controlled trials of treatments for epidermolysis bullosa acquisita were identified.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There is limited evidence that mucous membrane pemphigoid involving the eyes responds best to treatment with cyclophosphamide combined with corticosteroids. However, mucous membrane pemphigoid with mild to modest inflammatory activity responds to dapsone in most participants and may therefore be best treated with dapsone due to its lower side effect profile compared to cyclophosphamide. Treatment with mycophenolate mofetil combined with topical steroids seems worth considering in a future randomised controlled trial for mucous membrane pemphigoid.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-06-18 09:53:56 +0100" MODIFIED_BY="Diane A  Horsley">
<BACKGROUND MODIFIED="2008-06-18 09:40:04 +0100" MODIFIED_BY="Diane A  Horsley">
<CONDITION MODIFIED="2008-06-17 14:03:12 +0100" MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="3">Definition and Epidemiology</HEADING>
<P>Mucous membrane pemphigoid (MMP) and epidermolysis bullosa acquisita (EBA) are acquired autoimmune bullous disorders of the skin and mucous membranes (<LINK REF="REF-Gammon-1988" TYPE="REFERENCE">Gammon 1988</LINK>; <LINK REF="REF-Briggaman-1990" TYPE="REFERENCE">Briggaman 1990</LINK>; <LINK REF="REF-Fine-1990" TYPE="REFERENCE">Fine 1990</LINK>; <LINK REF="REF-Kirtschig-1998" TYPE="REFERENCE">Kirtschig 1998</LINK>; <LINK REF="REF-Wojnarowska-1998" TYPE="REFERENCE">Wojnarowska 1998</LINK>). Blisters, erosions, and later scar formation are characteristic features in both diseases and may lead to major disability (e.g. blindness) and life-threatening situations (e.g. respiratory obstruction). They are diseases of the elderly, but can also affect younger people and children (<LINK REF="STD-Edwards-1998" TYPE="STUDY">Edwards 1998</LINK>). For this review, MMP will replace the name "cicatricial pemphigoid", as suggested by <LINK REF="REF-Chan-2002" TYPE="REFERENCE">Chan 2002</LINK>. The incidence of MMP and EBA in Western Europe is calculated to be about 1 and 0.2 new cases per 1,000,000 inhabitants per year respectively (<LINK REF="REF-Bernard-1995" TYPE="REFERENCE">Bernard 1995</LINK>; <LINK REF="REF-Zillikens-1995" TYPE="REFERENCE">Zillikens 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Pathogenesis and Diagnosis</HEADING>
<P>Blister formation is thought to result from an antigen-antibody interaction, where IgG autoantibodies circulating in the bloodstream bind to cell adhesion complexes in the basement membrane zone of the skin (<LINK REF="REF-Liu-1993" TYPE="REFERENCE">Liu 1993</LINK>; <LINK REF="REF-Borradori-1995" TYPE="REFERENCE">Borradori 1995</LINK>; <LINK REF="REF-Lazarova-1996" TYPE="REFERENCE">Lazarova 1996</LINK>). In MMP and EBA, direct immunofluorescence (IF) demonstrates deposits of IgG and complement at the dermo-epidermal junction. Circulating autoantibodies may be detected using indirect IF. Immunofluorescence conducted on skin incubated in 1Molar sodium chloride helps to distinguish certain autoimmune bullous diseases such as EBA and a rare sub-group of MMP (in which fluorescence is at the floor of the blister) from bullous pemphigoid (BP) (in which fluorescence is usually at the roof) thus giving a more accurate diagnosis (<LINK REF="REF-Gammon-1984" TYPE="REFERENCE">Gammon 1984</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Clinical Course</HEADING>
<P>Both MMP and EBA are highly variable and often take a protracted course in contrast to BP, which usually remits within five years (<LINK REF="REF-Briggaman-1990" TYPE="REFERENCE">Briggaman 1990</LINK>; <LINK REF="REF-Wojnarowska-1998" TYPE="REFERENCE">Wojnarowska 1998</LINK>). Some people with localized disease (for example, only oral involvement in MMP) remain stable for years in the absence of aggressive therapy. Other people may develop rapidly progressive ocular (eye) involvement despite treatment with immunosuppressants. There are several different staging systems describing the changes seen in the eyes in inflammatory diseases. A system based on conjunctival changes, which are relevant in MMP and EBA, is described as follows (<LINK REF="STD-Foster-1986a" TYPE="STUDY">Foster 1986a</LINK>; <LINK REF="STD-Foster-1986b" TYPE="STUDY">Foster 1986b</LINK>):<BR/>
</P>
<UL>
<LI>stage I - chronic conjunctivitis with subepithelial fibrosis;</LI>
<LI>stage II - inferior fornix foreshortening;</LI>
<LI>stage III - symblepharon;</LI>
<LI>stage IV - end stage with ankyloblepharon, severe sicca syndrome, and ocular surface keratinization.</LI>
</UL>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2008-06-17 14:03:43 +0100" MODIFIED_BY="Cathy Bennett">
<P>The standard treatment for progressive disease (MMP and EBA) is the administration of systemic corticosteroids at a dose of 1 to 2 mg prednisolone equivalent per 1 kg of body weight, often combined with cyclophosphamide, azathioprine, or methotrexate. It is not known if any of these different immunosuppressive agents is particularly effective in suppressing the two diseases. Dapsone seems to be an alternative treatment in milder disease. These drugs, however, are accompanied by potentially life threatening complications and may still not lead to the desired therapeutic effect. Alternative treatment regimens involve antibiotics (tetracyclines, erythromycin), nicotinamide and immunoglobulins and these medications are usually better tolerated (<LINK REF="STD-Reiche-1998" TYPE="STUDY">Reiche 1998</LINK>; <LINK REF="REF-Dragan-1999" TYPE="REFERENCE">Dragan 1999</LINK>; <LINK REF="STD-Harman-1999" TYPE="STUDY">Harman 1999</LINK>; <LINK REF="STD-Foster-1999" TYPE="STUDY">Foster 1999</LINK>). Initial reports are promising, but it is not known whether recent alternative treatment regimens are equally or even more effective than traditional medication in people with progressive disease</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2008-06-18 09:40:04 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Evidence for the most effective immunosuppressive treatment option and other treatment options with less severe adverse effects is needed. A review is therefore required to determine:</P>
<OL>
<LI>the most effective drugs or interventions, with the least adverse effects;</LI>
<LI>whether combination therapy (for example, azathioprine plus steroids) offers any advantages over single therapy (for example, oral steroids alone);</LI>
<LI>whether antibiotics such as tetracyclines, erythromycin, dapsone, and sulphonamides useful;</LI>
<LI>whether systemic treatment is more effective than topical treatment in people with MMP or EBA.</LI>
</OL>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects of treatments for mucous membrane pemphigoid (MMP) and epidermolysis (EBA).</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-06-18 09:41:55 +0100" MODIFIED_BY="Diane A  Horsley">
<SELECTION_CRITERIA MODIFIED="2008-06-18 09:41:15 +0100" MODIFIED_BY="Diane A  Horsley">
<CRIT_STUDIES MODIFIED="2008-06-18 09:40:51 +0100" MODIFIED_BY="Diane A  Horsley">
<OL>
<LI>RCTs of interventions for MMP and EBA. Conclusions are based primarily on the findings of these RCTs.</LI>
<LI>Uncontrolled and controlled, but not randomized, therapeutic studies of MMP involving 5 or more participants and reports of EBA involving 2 or more participants identified from MEDLINE or EMBASE between their inception to February 2002 and studies of MMP or EBA involving 10 or more participants identified from MEDLINE or EMBASE between March 2002 and April 2005. These are listed as excluded studies, and their characteristics and results are reported briefly in the additional tables (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</LI>
</OL>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Anyone who received treatment after a diagnosis of MMP or EBA, confirmed by immunofluorescence studies.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Any therapeutic intervention used to treat MMP and EBA.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-06-18 09:41:15 +0100" MODIFIED_BY="Diane A  Horsley">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-06-17 14:04:48 +0100" MODIFIED_BY="Cathy Bennett">
<P>Rate of regression or of healing of the skin and mucosal lesions; in ocular disease, reduction of inflammation and no progression of conjunctival scarring are appropriate measures.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-06-18 09:41:15 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Duration of remission after stopping treatment.</P>
<P>Complications of the primary disease (MMP and EBA) such as scarring leading to severe complications (e.g. blindness, airway obstruction).</P>
<P>Adverse effects of treatment: infection, organ failure, allergic/toxic reactions etc.</P>
<P>Overall mortality.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-06-17 14:18:13 +0100" MODIFIED_BY="Cathy Bennett">
<ELECTRONIC_SEARCHES MODIFIED="2008-06-17 14:17:40 +0100" MODIFIED_BY="Cathy Bennett">
<P>We searched:<BR/>(a) The Cochrane Skin Group Specialised Register (7th April 2005) <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>
<BR/>(b) The Cochrane Controlled Trials Register (CENTRAL) (<I>The Cochrane Library Issue</I> 1, 2005) <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
<BR/>(c) MEDLINE / PubMed (from 1966 to April 2005) <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>
<BR/>(d) EMBASE (from 1980 to April 2005) <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>
<BR/>(e) www.controlled-trials.com (7th April 2005) and (f) www.clinicaltrials.gov (7th April 2005) <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>
</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-06-17 14:18:13 +0100" MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="4">References from published studies</HEADING>
<P>We searched the reference lists from identified studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Unpublished literature</HEADING>
<P>We contacted the trial author (C.S. Foster) who had conducted RCTs in the field to identify unpublished trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Conference proceedings</HEADING>
<P>Conference proceedings were not searched.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects</HEADING>
<P>A specific search for side effects studies was not carried out.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other</HEADING>
<P>The search was restricted to articles that had abstracts in English, French or German.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-06-18 09:41:55 +0100" MODIFIED_BY="Diane A  Horsley">
<P>
<B>
<BR/>
</B>
</P>
<STUDY_SELECTION MODIFIED="2008-06-17 14:20:00 +0100" MODIFIED_BY="Cathy Bennett">
<P>The primary objective was to identify and summarise data from RCTs, however, as MMP and EBA are rare diseases some evidence from non-randomised studies was also considered. These are listed in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table. Two authors (GK and NK) screened abstracts of potentially relevant studies.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-06-18 09:41:55 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Three authors (GK, NK, and DM) independently conducted data extraction and subsequently checked for discrepancies; any disagreements were resolved by discussion.</P>
<P>Details of eligible studies were extracted using a data extraction form that was developed based on the outcome measures. Studies that have been published in duplicate were included only once.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-06-17 14:21:24 +0100" MODIFIED_BY="Cathy Bennett" NOTES="&lt;p&gt;Author please check this heading as 'risk of bias' and 'methodological quality' are not always interchangeable terms.&lt;/p&gt;&lt;p&gt;Haven't actcivated all headings here, author please check and amend if required.&lt;/p&gt;" NOTES_MODIFIED="2008-06-17 14:21:24 +0100" NOTES_MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="4">Assessment of methodological quality</HEADING>
<P>The identified studies were individually critically appraised to assess methodological quality. For randomised trials, the key criteria were: method of randomisation, allocation concealment, blinded outcome assessment and inclusion of all randomised participants in the analysis.</P>
<P>Specific aspects were assessed for each study:<BR/>(a) the method of randomisation;<BR/>(b) the method of allocation to treatment groups;<BR/>(c) whether complete follow-up was achieved;<BR/>(d) the proportion of participants who did not complete the study and whether their outcomes were described and included in the analysis;<BR/>(e) whether the investigators blinded to the treatment allocation;<BR/>(f) whether the treatment and control groups comparable at entry;<BR/>(g) whether the groups treated were identically other than the named interventions.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2008-06-17 14:21:58 +0100" MODIFIED_BY="Cathy Bennett">
<P>For dichotomous outcomes, results are presented as risk ratios (RR) with 95% confidence intervals (CI). For the primary outcome measure, the proportion of participants with improvement greater than minimal is considered as treatment success. Data that has been recorded for three months is considered to reflect short term benefit and is analysed separately from data that was recorded for over a period of six months. The data at six months is considered as the primary endpoint (short term benefit).</P>
</EFFECT_MEASURES>
<DATA_SYNTHESIS MODIFIED="2008-06-17 14:22:24 +0100" MODIFIED_BY="Cathy Bennett">
<P>We initially planned to divide the data analysis into two groups:<BR/>(a) Trials where the diagnosis of MMP or EBA was confirmed by direct/indirect IF using intact skin;<BR/>(b) Trials where split skin was used for indirect IF- this procedure helps, although not completely, to separate EBA and a subgroup of MMP from BP participants;<BR/>however, this was unnecessary as no participant had indirect IF performed on split skin.</P>
<P>The results from the studies were to be pooled using meta-analysis based on random effects (DerSimonian and Laird model) and heterogeneity was to be assessed using I-squared (I<SUP>2</SUP>), however, pooling of data was not performed due to a lack of studies. Therefore, individual results are presented for each study.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-06-18 09:48:23 +0100" MODIFIED_BY="Diane A  Horsley">
<STUDY_DESCRIPTION MODIFIED="2008-06-18 09:44:42 +0100" MODIFIED_BY="Diane A  Horsley" NOTES="&lt;p&gt;Have not activated all headings here&lt;/p&gt;" NOTES_MODIFIED="2008-06-18 09:44:42 +0100" NOTES_MODIFIED_BY="Diane A  Horsley">
<SEARCH_RESULTS MODIFIED="2008-06-18 09:43:55 +0100" MODIFIED_BY="Diane A  Horsley" NOTES="&lt;p&gt;Have moved text to here from Results section - author please check.&lt;/p&gt;" NOTES_MODIFIED="2008-06-18 09:43:55 +0100" NOTES_MODIFIED_BY="Diane A  Horsley">
<P>We found 580 references in MEDLINE for MMP and EBA; 406 references for MMP and EBA in EMBASE . No RCTs were identified through searching the abstracts. Complete papers were sought and read for the references that had no abstracts in MEDLINE or EMBASE. Two RCTs of treatment for MMP were included in the review (<LINK REF="STD-Foster-1986a" TYPE="STUDY">Foster 1986a</LINK>; <LINK REF="STD-Foster-1986b" TYPE="STUDY">Foster 1986b</LINK>). No RCT for EBA was found.</P>
<P>Searching CENTRAL for controlled trials (CCTs and RCTs) 39 references were identified from MEDLINE and 3 references from EMBASE involving 'pemphigoid' or 'epidermolysis bullosa acquisita'. None of these studies were RCTs that met the inclusion criteria for MMP or EBA.</P>
<P>Eleven reports of uncontrolled studies of treatment for EBA involving two or more participants were found when searching MEDLINE and EMBASE were searched from their inception until February 2002. Two studies involved the same participants. The article by Edwards et al. is a follow up of the data presented by Kirtschig et al. (<LINK REF="STD-Edwards-1998" TYPE="STUDY">Edwards 1998</LINK>).</P>
<P>No studies for EBA involving 10 or more participants were identified when searching MEDLINE and EMBASE between March 2002 and April 2005.</P>
<P>A further 31 reports of mainly uncontrolled studies of treatment for MMP involving 5 or more participants were found when MEDLINE and EMBASE were searched until February 2002. Four of the reports represent follow ups of earlier studies (<LINK REF="STD-Rogers-1982" TYPE="STUDY">Rogers 1982</LINK>; <LINK REF="STD-Rogers-1988" TYPE="STUDY">Rogers 1988</LINK>; <LINK REF="STD-Mondino-1990" TYPE="STUDY">Mondino 1990</LINK>; <LINK REF="STD-Tauber-1991" TYPE="STUDY">Tauber 1991</LINK>).</P>
<P>Searching MEDLINE and EMBASE between March 2002 and April 2005 for MMP studies involving 10 or more participants 5 studies were identified (<LINK REF="STD-Gonzalez_x002d_Moles-2003" TYPE="STUDY">Gonzalez-Moles 2003</LINK>; <LINK REF="STD-Letko-2004" TYPE="STUDY">Letko 2004</LINK>; <LINK REF="STD-McCluskey-2004" TYPE="STUDY">McCluskey 2004</LINK>; <LINK REF="STD-Ingen_x002d_Housz-2005" TYPE="STUDY">Ingen-Housz 2005</LINK> ) data of Sami and Letko overlapping.</P>
<P>No studies were identified searching www.controlled-trial.com.<BR/>Searching www.clinicaltrials.gov no study was found for pemphigoid, one for EBA (<LINK REF="STD-Gordon-1997" TYPE="STUDY">Gordon 1997</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2008-06-18 09:44:42 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Two small RCTs involving participants with MMP affecting the eyes were identified (<I>see</I> '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'). Another 30, mainly uncontrolled, studies described the treatment of 5 or more participants with MMP. Eleven similar studies reporting the treatment of 2 or more participants with EBA were identified (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
<P>The first trial (<LINK REF="STD-Foster-1986a" TYPE="STUDY">Foster 1986a</LINK>) included 24 participants with bilateral stage III MMP affecting the eyes. Treatment consisted of either a dextrose placebo plus prednisone, or cyclophosphamide 2 mg/kg/day plus prednisone. The initial prednisone dosage was 1 mg/kg body weight per day. The dosage was then tapered according to the protocol. The prednisone was tapered until completely discontinued in the cyclophosphamide group. In the prednisone only group, a maintenance dose of 0.25 mg/kg every other day was administered, unless drug-induced complications or treatment failures were judged to preclude continued treatment. There was a six month intervention period and after that a six month follow-up period. The effect of the treatment was judged after the six month intervention period.</P>
<P>The second trial (<LINK REF="STD-Foster-1986b" TYPE="STUDY">Foster 1986b</LINK>), conducted by the same investigators, involved 40 participants with active, progressive stage III MMP affecting the conjunctiva. Dapsone 2 mg/kg/d was given to one group, cyclophosphamide 2 mg/kg/d to the other group. The study protocol was identical to that described for the first trial. It was not explicitly stated whether or not these participants received prednisone in addition to dapsone or cyclophosphamide initially. In order to clarify the confusion, the trial author was contacted. He stated: "we typically treated patients with a short course of prednisone while induction with an immunomodulator was being accomplished". There was a six month observation period and the outcome was judged at the end of the six months.</P>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-06-17 14:33:55 +0100" MODIFIED_BY="Cathy Bennett" NOTES="&lt;p&gt;Headings not activated here.  Author to check and amend if required.&lt;/p&gt;" NOTES_MODIFIED="2008-06-17 14:33:55 +0100" NOTES_MODIFIED_BY="Cathy Bennett">
<P>The clinical diagnosis of mucous membrane pemphigoid in the two RCTs that compared treatment of progressive MMP affecting the eyes was confirmed by direct immunofluorescence on intact skin (<I>see</I> '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'). Both were small, randomised, double-blind studies comparing two active treatments.</P>
<P>The disadvantages in both studies were the small numbers of participants (24 and 40 participants) and the lack of clarity concerning the drug regimen in the follow-up period.</P>
<P>There is some doubt about the concealment of allocation, as the trial author who carried out the randomisation also treated the participants, monitored the drugs and carried out the intervention.</P>
<P>In the first trial the participants received either dextrose placebo plus prednisone or cyclophosphamide plus prednisone. In the second trial, the participants received either dapsone or cyclophosphamide (it is not stated if the tablets are exactly the same).</P>
<P>Otherwise the studies were of good methodological quality because:<BR/>1) the method of randomisation was acceptable: A table of random numbers, "incomplete block design", use of sequentially numbered sealed envelopes;<BR/>2) disease activity was assessed by a masked observer;<BR/>3) there were no drop-outs.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-06-18 09:48:23 +0100" MODIFIED_BY="Diane A  Horsley" NOTES="&lt;p&gt;Author i have moved some of this text round to the Results of the search section. The subheadings in that section could then be activated (but not the excluded studies heading).  Hope this was OK.&lt;/p&gt;" NOTES_MODIFIED="2008-06-18 09:48:23 +0100" NOTES_MODIFIED_BY="Diane A  Horsley">
<SUBSECTION>
<HEADING LEVEL="3">Included MMP studies</HEADING>
<P>The two RCTs compared treatment of progressive MMP affecting the eyes (<I>see</I> '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'). One included 24 participants with bilateral ocular, stage III MMP (symblepharon formation) in which treatment with cyclophosphamide plus prednisone versus prednisone alone was tested. The second trial included 40 participants with stage III ocular MMP in which treatment with dapsone versus cyclophosphamide was tested. It did not mention if both eyes were affected. The 64 participants in the two trials were part of a study population of 130 participants with MMP involving the eyes, collected between 1975 and 1985 at the Immunology and Uveitis Unit, Harvard Medical School, Boston, USA. All 130 participants had bulbar conjunctival biopsies for histological investigation and direct immunofluorescence. All 64 RCT participants showed linear deposition of immunoglobulins at the basement membrane zone on direct IF.</P>
<P>One gets the impression from the article that all consecutive new participants, who fulfilled the inclusion criteria, were entered in a randomised fashion initially to the first trial, and once this was completed, then to the second trial. However, this is not clearly stated. All participants exhibited stage III conjunctival changes for pemphigoid and were judged, after elimination of potential confounding variables (trichiasis, districhasis, lagophthalmos, etc.) to have active disease. Participants with a history of chronic ocular drug use prior to disease onset were excluded, as were participants with a history of conjunctival scarring secondary to infection, trauma, malignancy, or systemic disease (e.g. Stevens-Johnson syndrome and sarcoidosis). No participants were eliminated from the study once it began, and none had contraindications to immunosuppression. All participants agreed to a follow-up period of one year.</P>
<P>All participants entered into the two trials completed the studies, none were lost to follow up.</P>
<P>Trial 1 showed a superior effect of cyclophosphamide and prednisone in combination compared to prednisone alone in the treatment of bilateral stage III MMP involving the eyes with regard to primary outcome measure (a) and secondary outcome measure (c) (see <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The clinical evidence of active conjunctival inflammation completely subsided in 12 of 12 participants treated with cyclophosphamide, and the globes appeared white and quiet bilaterally. No evidence of recurrent conjunctival inflammation appeared during prednisone taper and discontinuation, nor did cicatrization of the conjunctiva progress during the six months of the trial (short term benefit) and the six months observation period (long term benefit). The visual acuity was maintained in all participants and improved in eight. In contrast, conjunctival inflammation subsided and the globes appeared white and quiet in only 5 of 12 participants treated with prednisone alone. These five showed no evidence of progressive conjunctival cicatrization for the six month duration of the study period (outcome measure c). When the prednisone was tapered further at the end of the six months, conjunctival inflammation recurred in all five participants. The difference in clinical outcome is statistically significant (Chi-square analysis: P &lt; 0.005, relative risk 2.40, 95% confidence interval 1.23 to 4.69; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) <B>NB please check, are these figures correct - have I put correct link here?</B>. It was not clear from the article whether the treatment was stopped after the six month treatment period. In discussing the treatment with the trial author (C.S. Foster) the recommended duration of treatment was found to be at least one year and usually longer.</P>
<P>In trial 2, cyclophosphamide was shown to be superior to dapsone, with regard to outcome measure (a), in the treatment of participants with MMP and severe (4+) inflammation of the eyes (degree of conjunctival inflammation graded 0 to 4+, no further explanation of grading stated). All 20 of the cyclophosphamide therapy participants responded to treatment with an abolition of all clinical evidence of conjunctival inflammation and no evidence of conjunctival scarring throughout the six month observation period. However, only 14 of the 20 dapsone-treated participants responded to treatment (relative risk 1.43, 95% confidence interval 1.07 to 1.90;<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>)<B> NB please check are these figures correct - have I put correct link here?</B>. Four participants responded incompletely to dapsone, with reduction of inflammation, and 2 participants failed to respond at all within 12 weeks. The six dapsone treatment failures included all four of the participants with 4+ conjunctival inflammation prior to therapy. The two remaining treatment failures had 3+ activity before treatment. All six participants responded well to cyclophosphamide therapy after the three months treatment with dapsone that had failed to improve their disease. No results were mentioned regarding outcome measure (c).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse Effects</HEADING>
<P>Adverse effects observed in both trials are listed in <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.</P>
<P>None of the participants died during treatment or follow up in either trial (outcome measure e)</P>
<P>Trial 1: None of the participants withdrew from systemic immunosuppression due to adverse effects, and none required hospitalization for intervention for any adverse effect. Ten of 12 participants suffered varying degrees of hair loss, but none needed to wear a wig. The hair loss was reversible when treatment with cyclophosphamide was discontinued. Leukopenia was a routine finding in all participants successfully treated with cyclophosphamide. Foster states: "we have found significant depression in the white blood cell count to be an absolute requirement for achieving the desired therapeutic effect of cyclophosphamide". The leukopenia was reversible, and the cyclophosphamide dose was adjusted to achieve a leukocyte count between 2,500 to 4,000 white cells/microlitre. Macrocytic anaemia, present in 12 of 12 participants, was asymptomatic and of mild to moderate degree. Microcytic haematuria was discovered in routine urinalysis; an alteration in timing of cyclophosphamide administration and increased fluid intake eliminated this potentially serious side effect. Each of the participants in the prednisone group experienced prednisone-induced complications (<I>see</I> <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>, 'Adverse effects').</P>
<P>Trial 2: Most participants receiving cyclophosphamide showed alopecia, anaemia and leukopenia, the exact numbers are not stated. Microcytic haematuria developed in two participants necessitating a reduction of cyclophosphamide. Evidence of haemolysis was found in 19 of 20 dapsone treated participants; for less common adverse effects see <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>, 'Adverse effects'. Foster emphasizes that dapsone is not a benign drug and death may occur as a result of agranulocytosis, aplastic anaemia, or haemolytic anaemia.</P>
<P>Outcome measure (b) is not applicable in either trial, because none of the participants stopped treatment during the described follow-up period.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-06-18 09:50:40 +0100" MODIFIED_BY="Diane A  Horsley" NOTES="&lt;p&gt;Not all possible subheadings activated.&lt;/p&gt;" NOTES_MODIFIED="2008-06-18 09:50:40 +0100" NOTES_MODIFIED_BY="Diane A  Horsley">
<SUMMARY_OF_RESULTS MODIFIED="2008-06-18 09:50:40 +0100" MODIFIED_BY="Diane A  Horsley">
<P>It is not possible to draw definite conclusions as to the best treatment for MMP or EBA.</P>
<P>Long-term corticosteroid treatment puts participants at risk of serious complications (for example development of hypertension, diabetes mellitus, and osteoporosis) and seems to be less effective than cyclophosphamide in suppressing scarring MMP involving the eyes. Foster believes that systemic immunosuppression with cyclophosphamide poses fewer risks if properly used compared with long-term corticosteroid therapy.</P>
<P>The second trial shows that cyclophosphamide is more effective in suppressing conjunctival inflammation in ocular MMP compared to treatment with dapsone. However, cyclophosphamide usually shows more adverse effects. Most participants will have alopecia, some degree of leukopenia and anaemia. Male sterility and haemorrhagic cystitis may occur and there is a potential for malignancy (DNA damage). With dapsone, some degree of anaemia is common in most participants. There are potentially serious adverse effects in treatment with dapsone, but these are very rare. They include severe haemolytic anaemia, methaemoglobinaemia, agranulocytosis, neuropathy and the dapsone syndrome (rash with fever and eosinophilia). Dapsone syndrome requires the immediate cessation of dapsone as it may progress to exfoliative dermatitis and death. In general, most dermatologists will have used dapsone regularly, but most are probably not familiar with the use of cyclophosphamide (because of the fear of side effects).</P>
<P>According to trial two, most MMP participants with mild to modest inflammatory activity involving the eyes seemed to respond well to dapsone (14 of 16 participants with mild to modest inflammatory activity improved). Therefore, Foster concludes that dapsone is a reasonable first choice medication for participants with MMP without very active and rapidly progressive disease, provided they are not glucose-6-phosphate dehydrogenase (G6PD) deficient (participants who are G6PD deficient will develop severe anaemia when taking dapsone). An increasing dose starting at 25 mg/day, then increasing to 50 mg/day after 4 weeks and then to 100 mg/day after another 4 weeks is recommended, with dosage adjustments based on therapeutic response and drug tolerance. The haemolysis is greatest at four weeks into treatment. A response can be expected within four weeks of treatment (<LINK REF="STD-Foster-1986b" TYPE="STUDY">Foster 1986b</LINK>). In the absence of a placebo group in either study, it is not possible to say how much better any of the tested drugs are than placebo.</P>
<P>Thirty one (36 references; 5 of the 36 references presented follow-up data of previous studies) additional mainly uncontrolled studies of treatment in MMP, involving 5 or more participants were identified (<I>see</I> '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table).</P>
<P>Eighteen studies investigated participants with oral and generalized MMP of which 8 comment on sulphur drugs (dapsone, sulfapyridine, sulfamethoxypyridazine); 84 of 131 participants appeared to benefit from this medication.</P>
<P>Of the 18 studies, 3 discuss the use of oral versus topical steroids in oral MMP, the results of which are controversial. One group reports about the use of a gingival tray for the application of 0.05% clobetasol propionate plus 100,000 IU/cc of nystatin in orabase paste (<LINK REF="STD-Gonzalez_x002d_Moles-2003" TYPE="STUDY">Gonzalez-Moles 2003</LINK>).</P>
<P>Minocycline treatment is reported in 25 participants with generalized MMP. This medication seems beneficial in oral MMP (orodynia), although little effect is seen in ocular disease.</P>
<P>Mycophenolate mofetil (MMF) treatment (1.5 to 2g daily) was used in a heterogeneous (oral &gt; generalized) group of 14 participants with proven MMP (<LINK REF="STD-Ingen_x002d_Housz-2005" TYPE="STUDY">Ingen-Housz 2005</LINK>). MMF treatment for MMP may be a promising option for participants with moderate and severe disease; however the authors think that it should not replace cyclophosphamide in severe sight or life threatening MMP. Compared to other immunosuppressive therapies (e.g. cyclophosphamide) adverse effects seem reasonable. RCTs are needed in order to evaluate its true value in the treatment of MMP.</P>
<P>Nineteen articles present participants with mainly ocular MMP. Three of these studies support the effectiveness of sulphur drugs in moderate ocular MMP. One study (<LINK REF="STD-Elder-1996" TYPE="STUDY">Elder 1996</LINK>) found that sulfapyridine was clinically effective in 50% of participants with moderate or marked inflammation, and had few side effects (<LINK REF="STD-Tauber-1991" TYPE="STUDY">Tauber 1991</LINK>; <LINK REF="STD-Fern-1992" TYPE="STUDY">Fern 1992</LINK>; <LINK REF="STD-Elder-1996" TYPE="STUDY">Elder 1996</LINK>). See '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table.</P>
<P>Early studies suggest that ocular MMP shows less progression when participants are immunosuppressed; treatment with cyclophosphamide in addition to oral corticosteroids seems more effective than for example azathioprine (<LINK REF="STD-Mondino-1990" TYPE="STUDY">Mondino 1990</LINK>). Also methotrexate (MTX) is reported to prevent the progression of conjunctival cicatrisation (<LINK REF="STD-McCluskey-2004" TYPE="STUDY">McCluskey 2004</LINK>).</P>
<P>Recent trials report topical mitomycin C to be beneficial in severe ocular MMP (<LINK REF="STD-Secchi-1996" TYPE="STUDY">Secchi 1996</LINK>; <LINK REF="STD-Donnenfeld-1999" TYPE="STUDY">Donnenfeld 1999</LINK>).</P>
<P>The use of intravenous immunoglobulins (IVIg) is described in three reports by the same group of investigators (<LINK REF="STD-Foster-1999" TYPE="STUDY">Foster 1999</LINK>; <LINK REF="STD-Letko-2004" TYPE="STUDY">Letko 2004</LINK>) the reports by Letko and Sami seem to involve the same participants. In ten participants with ocular MMP resistant to conventional treatment IVIg were used with apparent success (<LINK REF="STD-Foster-1999" TYPE="STUDY">Foster 1999</LINK>). A non-randomised comparison between conventional immunosuppressive and IVIg therapies investigated eight participants in each group (<LINK REF="STD-Letko-2004" TYPE="STUDY">Letko 2004</LINK>). All patients received (various) immunosuppressive treatment as an initial treatment before treatment with IVIg was started. The authors recommend a RCT to confirm the results and determine the optimal protocol.</P>
<P>Treatment with topical tacrolimus, topical cyclosporine, tetracycline and nicotinamide, colchicine, thalidomide, leflunomide, plasmapheresis, autologous serum application to ocular epithelial defects and "biologicals" like TNF alpha receptor (etanercept), anti-CD25 (daclizumab), anti-CD20 (rituximab) has been described in single cases.</P>
<P>We identified 11 articles on uncontrolled studies for the treatment of EBA involving two or more participants, detailing results in 20 adults and 11 children (<I>see</I> '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table). The adult participants were treated with various medications including systemic corticosteroids, immunosuppressants, dapsone, colchicine and intravenous immunoglobulins; it is not possible to draw any conclusions regarding the superiority of any of these treatments. Most children were treated with systemic corticosteroids and/or dapsone. No reliable evidence-based recommendation can be given for the treatment of EBA at present. A number of agents have been suggested (see '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table), but this evidence is from a very small case-series and is not reliable in the absence of a suitable control group. Collectively, the uncontrolled studies of EBA suggest that children seem to respond to treatment with a combination of systemic corticosteroids and dapsone. However, in children, EBA seems to remit within a few years, and it is not possible to judge if this is due to treatment or represents a spontaneous remission (<LINK REF="REF-Briggaman-1990" TYPE="REFERENCE">Briggaman 1990</LINK>; <LINK REF="STD-Edwards-1998" TYPE="STUDY">Edwards 1998</LINK>).<BR/>No final results could be obtained regarding the one prospective uncontrolled trial for EBA (<LINK REF="STD-Gordon-1997" TYPE="STUDY">Gordon 1997</LINK>)</P>
</SUMMARY_OF_RESULTS>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-06-18 09:53:56 +0100" MODIFIED_BY="Diane A  Horsley">
<IMPLICATIONS_PRACTICE>
<P>Based on these two identified RCTs:<BR/>1. In MMP involving the eyes, cyclophosphamide in combination with short term corticosteroids may be more effective in suppressing inflammation of the conjunctiva and progression of scarring than long-term corticosteroids or dapsone; however, both cyclophosphamide and corticosteroids may have severe adverse effects in the long term.<BR/>2. In MMP with mild to modest inflammation involving the eyes, dapsone may be an effective first choice treatment in most patients, because the adverse effect profile of dapsone is more tolerable for most patients compared to cyclophosphamide and long term corticosteroids. Serious adverse effects in dapsone are very rare; they are only reported in single case reports.<BR/>No reliable evidence-based recommendation can be given for the treatment of EBA.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-06-18 09:53:56 +0100" MODIFIED_BY="Diane A  Horsley">
<P>More research is urgently required. As MMP and EBA are rare diseases, international multicentre RCTs involving larger numbers of participants may be necessary to assess the best treatment for these diseases. Also, collaborating to improve the collection of case data would be worthwhile in order to overcome the many deficiencies of case series due to the possibility of selection bias; comprehensive case detection alleviates this.<BR/>Treatments with anti-inflammatory antibiotics such as tetracycline, minocycline, and newer medications like anti-TNF alpha antibodies might be as effective as dapsone and have the benefit of fewer adverse effects, and are worthy of further investigation. For example a RCT for the treatment of bullous pemphigoid suggests some merit in the use of tetracycline and nicotinamide (<LINK REF="REF-Fivenson-1994" TYPE="REFERENCE">Fivenson 1994</LINK>).</P>
<P>Treatment with Mycophenolate mofetil (MMF) combined with topical steroids seems worth considering in a future RCT.</P>
<P>RCT suggestion: Mycophenolate mofetil plus topical corticosteroids versus dapsone plus topical corticosteroids (or versus cyclophosphamide plus topical steroids) in moderate and severe MMP.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-06-18 09:54:05 +0100" MODIFIED_BY="Diane A  Horsley">
<P>We thank Anna Truelove for reviewing the manuscript and her helpful linguistic comments.</P>
<P>We thank the Nuffield Trust Fellowship Scheme for the financial support in the preparation of this review.</P>
<P>GK thanks the "Deutsche Forschungsgemeinschaft" (DFG) for their financial support in the past, which enabled her to build up her knowledge of autoimmune blistering diseases. This knowledge was of great value when conducting this review. Philippa Middleton's contribution to the up-date is greatly appreciated.</P>
<P>The editorial base would like to thank the following people who were the external referees for this review:<BR/>Tony Egan, Philippe Bernard, Alex Foss (content experts) and Margaret Delia (consumer).</P>
<P>We want to thank Ingrid Riphagen (IR), information specialist VUmc Amsterdam, and Finola Delamere (FD), Trials Search Co-ordinator, Cochrane Skin Group, Nottingham, UK, for their continuous excellent support when searching the literature for treatment in MMP and EBA.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Fenella Wojnarowska was invited to speak at a conference on Treatment of Autoimmune Bullous Diseases organised by Bayer, who manufacture IVIgs. Her expenses and an honorarium were paid by Bayer.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>1. GK conceived the idea of the review, contributed to the writing of the protocol, extraction of data, analysis of the results, and the writing of the systematic review.<BR/>2. NPK contributed to the writing of the protocol, extraction of data, analysis of the results, and the writing of the systematic review.<BR/>3. DFM contributed to the writing of the protocol, extraction of data, analysis of the results, and the writing of the systematic review.<BR/>4. FW contributed to the writing of the protocol and analysis of the results.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2015-02-20 11:17:12 +0000" MODIFIED_BY="Laura E Prescott">
<P>The conclusion is so certain that the addition of new information will not change it, and there is unlikely to be any more research done on this topic. There were no ongoing studies or studies awaiting classification listed in the last published review, and a search of MEDLINE and Embase in 2014 found no recent results.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-06-18 11:00:50 +0100" MODIFIED_BY="Diane A  Horsley">
<STUDIES MODIFIED="2008-06-18 11:00:50 +0100" MODIFIED_BY="Diane A  Horsley">
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Foster-1986a" NAME="Foster 1986a" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Foster, Stephen</AU>
<TI>Cicatricial pemphigoid</TI>
<SO>Transactions of the American Ophthalmological Society</SO>
<YR>1986</YR>
<VL>84</VL>
<PG>527-663 (pp 619-38)</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3804625"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Foster-1986b" NAME="Foster 1986b" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Foster, Stephen</AU>
<TI>Cicatricial Pemphigoid</TI>
<SO>Transactions of the American Ophthalmological Society</SO>
<YR>1986</YR>
<VL>84</VL>
<PG>527-663 (pp 638-40)</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3804625"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-06-18 11:00:50 +0100" MODIFIED_BY="Diane A  Horsley">
<STUDY DATA_SOURCE="PUB" ID="STD-Arpey-1991" NAME="Arpey 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Arpey CJ, Elewski BE, Moritz DK, Gammon WR. Childhood epidermolysis bullosa acquisita. J Am Acad Dermatol 1991;24:706-714.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arpey CJ, Elewski BE, Moritz DK, Gammon WR</AU>
<TI>Childhood epidermolysis bullosa acquisita</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1991</YR>
<VL>24</VL>
<PG>706-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Axt-1995" MODIFIED="2008-06-18 10:23:15 +0100" MODIFIED_BY="Diane A  Horsley" NAME="Axt 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-06-18 10:23:15 +0100" MODIFIED_BY="Diane A  Horsley" NOTES="&lt;p&gt;Axt M, Wever S, Baier G, et al. [Cicatricial pemphigoid--a therapeutic problem]. Hautarzt 1995;46(9):620-627.&lt;/p&gt;" NOTES_MODIFIED="2008-06-18 10:23:15 +0100" NOTES_MODIFIED_BY="Diane A  Horsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Axt M, Wever S, Baier G, Bogdan S, Hashimoto T, Bröcker EB, et al</AU>
<TI>Cicatricial pemphigoid--a therapeutic problem</TI>
<SO>Hautarzt</SO>
<YR>1995</YR>
<VL>46</VL>
<NO>9</NO>
<PG>620-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bialasiewicz-1994" MODIFIED="2008-06-18 10:20:08 +0100" MODIFIED_BY="Diane A  Horsley" NAME="Bialasiewicz 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-06-18 10:20:08 +0100" MODIFIED_BY="Diane A  Horsley" NOTES="&lt;p&gt;Bialasiewicz AA, Forster W, Radig H, et al. [Syngeneic transplantation of nasal mucosa and azathioprine medication for therapy of cicatricial ocular mucous membrane pemphigoid. Study of 9 patients with 11 eyes]. Ophthalmologe 1994;91(2):244-250.&lt;/p&gt;" NOTES_MODIFIED="2008-06-18 10:20:08 +0100" NOTES_MODIFIED_BY="Diane A  Horsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bialasiewicz AA, Forster W, Radig H, Hüttenbrink KB, Grewe S, Busse H</AU>
<TI>Syngeneic transplantation of nasal mucosa and azathioprine medication for therapy of cicatricial ocular mucous membrane pemphigoid. Study of 9 patients with 11 eyes</TI>
<SO>Ophthalmologe</SO>
<YR>1994</YR>
<VL>91</VL>
<NO>2</NO>
<PG>244-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Callot_x002d_Mellot-1997" MODIFIED="2008-06-18 10:21:16 +0100" MODIFIED_BY="Diane A  Horsley" NAME="Callot-Mellot 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-06-18 10:21:16 +0100" MODIFIED_BY="Diane A  Horsley" NOTES="&lt;p&gt;Callot-Mellot C, Bodemer C, Caux F, et al. Epidermolysis bullosa acquisita in childhood. Arch Dermatol 1997;133(9):1122-1126.&lt;/p&gt;" NOTES_MODIFIED="2008-06-18 10:21:16 +0100" NOTES_MODIFIED_BY="Diane A  Horsley" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Callot-Mellot C, Bodemer C, Caux F, Bourgault-Villada I, Fraitag S, Goudié G, et al</AU>
<TI>Epidermolysis bullosa acquisita in childhood</TI>
<SO>Archives of Dermatology</SO>
<YR>1997</YR>
<VL>133</VL>
<NO>9</NO>
<PG>1122-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carbone-1998" MODIFIED="2008-06-18 10:22:20 +0100" MODIFIED_BY="Diane A  Horsley" NAME="Carbone 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-06-18 10:22:20 +0100" MODIFIED_BY="Diane A  Horsley" NOTES="&lt;p&gt;Carbone M, Carrozzo M, Castellano S, et al. Systemic corticosteroid therapy of oral vesiculoerosive diseases (OVED). An open trial. Minerva Stomatol 1998;47(10):479-487.&lt;/p&gt;" NOTES_MODIFIED="2008-06-18 10:22:20 +0100" NOTES_MODIFIED_BY="Diane A  Horsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carbone M, Carrozzo M, Castellano S, Conrotto D, Broccoletti R, Gandolfo S</AU>
<TI>Systemic corticosteroid therapy of oral vesiculoerosive diseases (OVED). An open trial</TI>
<SO>Minerva Stomatologica</SO>
<YR>1998</YR>
<VL>47</VL>
<NO>10</NO>
<PG>479-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carrozzo-1997" NAME="Carrozzo 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Carrozzo M, Carbone M, Broccoletti R, Garzino-Demo P, Gandolfo S. [Therapeutic management of mucous membrane pemphigoid. Report of 11 cases]. Minerva Stomatol 1997;46(10):553-559.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carrozzo M, Carbone M, Broccoletti R, Garzino-Demo P, Gandolfo S</AU>
<TI>Therapeutic management of mucous membrane pemphigoid. Report of 11 cases:</TI>
<SO>Minerva Stomatologica</SO>
<YR>1997</YR>
<VL>46</VL>
<NO>10</NO>
<PG>553-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cunningham-1996" NAME="Cunningham 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Cunningham BB, Kirchmann TT, Woodley D. Colchicine for epidermolysis bullosa acquisita. J Am Acad Dermatol 1996;34(5 Pt 1):781-784.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cunningham BB, Kirchmann TT, Woodley D</AU>
<TI>Colchicine for epidermolysis bullosa acquisita</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1996</YR>
<VL>34</VL>
<NO>5 Pt 1</NO>
<PG>781-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Donnenfeld-1999" MODIFIED="2008-06-18 10:24:25 +0100" MODIFIED_BY="Diane A  Horsley" NAME="Donnenfeld 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-06-18 10:24:25 +0100" MODIFIED_BY="Diane A  Horsley" NOTES="&lt;p&gt;Donnenfeld ED, Perry HD, Wallerstein A, et al. Subconjunctival mitomycin C for the treatment of ocular cicatricial pemphigoid. Ophthalmology 1999;106(1):72-79.&lt;/p&gt;" NOTES_MODIFIED="2008-06-18 10:24:25 +0100" NOTES_MODIFIED_BY="Diane A  Horsley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donnenfeld ED, Perry HD, Wallerstein A, Caronia RM, Kanellopoulos AJ, Sforza PD, et al</AU>
<TI>Subconjunctival mitomycin C for the treatment of ocular cicatricial pemphigoid</TI>
<SO>Ophthalmology</SO>
<YR>1999</YR>
<VL>106</VL>
<NO>1</NO>
<PG>72-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Edwards-1998" MODIFIED="2008-06-18 10:59:29 +0100" MODIFIED_BY="Diane A  Horsley" NAME="Edwards 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-06-18 10:59:29 +0100" MODIFIED_BY="Diane A  Horsley" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Edwards S, Wakelin SH, Wojnarowska F, Marsden RA, Kirtschig G, Bhogal B, et al</AU>
<TI>Bullous pemphigoid and epidermolysis bullosa acquisita: presentation, prognosis, and immunopathology in 11 children</TI>
<SO>Pediatric Dermatology</SO>
<YR>1998</YR>
<VL>15</VL>
<NO>3</NO>
<PG>184-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kirtschig G, Wojnarowska F, Marsden RA, Edwards S, Bhogal B, Black MM</AU>
<TI>Acquired bullous diseases of childhood: re-evaluation of diagnosis by indirect immunofluorescence examination on 1 M NaCl split skin and immunoblotting</TI>
<SO>British Journal of Dermatology</SO>
<YR>1994</YR>
<VL>130</VL>
<NO>5</NO>
<PG>610-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elder-1995" NAME="Elder 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Elder MJ, Lightman S, Dart JK. Role of cyclophosphamide and high dose steroid in ocular cicatricial pemphigoid. Br J Ophthalmol 1995;79(3):264-266.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Elder MJ, Lightman S, Dart JK</AU>
<TI>Role of cyclophosphamide and high dose steroid in ocular cicatricial pemphigoid</TI>
<SO>The British Journal of Ophthalmology</SO>
<YR>1995</YR>
<VL>79</VL>
<NO>3</NO>
<PG>264-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elder-1996" NAME="Elder 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elder MJ, Leonard J, Dart JK</AU>
<TI>Sulphapyridine - a new agent for the treatment of ocular cicatricial pemphigoid</TI>
<SO>The British Journal of Ophthalmology</SO>
<YR>1996</YR>
<VL>80</VL>
<NO>6</NO>
<PG>549-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fern-1992" NAME="Fern 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Fern AI, Jay JL, Young H, MacKie R. Dapsone therapy for the acute inflammatory phase of ocular pemphigoid. Br J Ophthalmol 1992;76(6):332-335.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fern AI, Jay JL, Young H, MacKie R</AU>
<TI>Dapsone therapy for the acute inflammatory phase of ocular pemphigoid</TI>
<SO>The British Journal of Ophthalmology</SO>
<YR>1992</YR>
<VL>76</VL>
<NO>6</NO>
<PG>332-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Foster-1982" NAME="Foster 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Foster CS, Wilson LA, Ekins MB. Immunosuppressive therapy for progressive ocular cicatricial pemphigoid. Ophthalmology 1982;89(4):340-353.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Foster CS, Wilson LA, Ekins MB</AU>
<TI>Immunosuppressive therapy for progressive ocular cicatricial pemphigoid</TI>
<SO>Ophthalmology</SO>
<YR>1982</YR>
<VL>89</VL>
<NO>4</NO>
<PG>340-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Foster-1999" NAME="Foster 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Foster CS, Ahmed AR</AU>
<TI>Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study</TI>
<SO>Ophthalmology</SO>
<YR>1999</YR>
<VL>106</VL>
<NO>11</NO>
<PG>2136-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Francis-1990" NAME="Francis 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Francis IC, McCluskey PJ, Walls RS, Wakefield D, Brewer JM. Ocular cicatricial pemphigoid. Aust N Z J Ophthalmol 1990;18(2):143-150.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Francis IC, McCluskey PJ, Walls RS, Wakefield D, Brewer JM</AU>
<TI>Ocular cicatricial pemphigoid</TI>
<SO>Australian and New Zealand Journal Ophthalmology</SO>
<YR>1990</YR>
<VL>18</VL>
<NO>2</NO>
<PG>143-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gillies-1996" NAME="Gillies 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Gillies M, Francis I, McCluskey P, Wakefield D. Local interferon alfa-2b for ocular cicatricial pemphigoid [letter]. Br J Ophthalmol 1996;80(10):927.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gillies M, Francis I, McCluskey P, Wakefield D</AU>
<TI>Local interferon alfa-2b for ocular cicatricial pemphigoid [letter]</TI>
<SO>The British Journal of Ophthalmology</SO>
<YR>1996</YR>
<VL>80</VL>
<NO>10</NO>
<PG>927</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonzalez_x002d_Moles-2003" NAME="Gonzalez-Moles 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez-Moles MA, Ruiz-Avila I, Rodriguez-Archilla A, Morales-Garcia P, Mesa-Aguado F, Bascones-Martinez A, et al</AU>
<TI>Treatment of severe erosive gingival lesions by topical application of clobetasol propionate in custom trays</TI>
<SO>Oral Surgery Oral Medicine Oral Pathology Oral Radiology &amp; Endodontics</SO>
<YR>2003</YR>
<VL>95</VL>
<PG>688-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gordon-1997" NAME="Gordon 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Gordon KB, Chan LS, Woodley DT. Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy. Br J Dermatol 1997;136(3):415-20.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gordon KB, Chan LS, Woodley DT</AU>
<TI>Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy</TI>
<SO>British Journal of Dermatology</SO>
<YR>1997</YR>
<VL>136</VL>
<NO>3</NO>
<PG>415-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;CI emailed - no reply&lt;/p&gt;" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Gordon KB</AU>
<TI>Epidermolysis bullosa acquisita: oral methoxsalen (8-MOP) is administered 90 minutes prior to leukapheresis</TI>
<SO>NCT00004359</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gupta-1990" NAME="Gupta 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Gupta AK, Ellis CN, Nickoloff BJ, et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol 1990;126(3):339-350.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gupta AK, Ellis CN, Nickoloff BJ, et al</AU>
<TI>Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis</TI>
<SO>Archives of Dermatology</SO>
<YR>1990</YR>
<VL>126</VL>
<NO>3</NO>
<PG>339-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanson-1988" NAME="Hanson 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Hanson RD, Olsen KD, Rogers RSd. Upper aerodigestive tract manifestations of cicatricial pemphigoid. Ann Otol Rhinol Laryngol 1988;97(5 Pt 1):493-499.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hanson RD, Olsen KD, Rogers RS</AU>
<TI>Upper aerodigestive tract manifestations of cicatricial pemphigoid</TI>
<SO>The Annals Otology, Rhinology, and Laryngology</SO>
<YR>1988</YR>
<VL>97</VL>
<NO>5 Pt 1</NO>
<PG>493-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harman-1999" NAME="Harman 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Harman KE, Black MM. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases [see comments]. Br J Dermatol 1999;140(5):865-74.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Harman KE, Black MM</AU>
<TI>High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases [see comments]</TI>
<SO>British Journal of Dermatology</SO>
<YR>1999</YR>
<VL>140</VL>
<NO>5</NO>
<PG>865-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ingen_x002d_Housz-2005" NAME="Ingen-Housz 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ingen-Housz-Oro S, Prost-Squarcioni C, Pascal F, Doan S, Brette MD, Bachelez H et al</AU>
<TI>Cicatricial pemphigoid: treatment with mycophenolate mofetil</TI>
<SO>Annales de Dermatologie et de Venereologie</SO>
<YR>2005</YR>
<VL>132</VL>
<PG>13-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lamey-1992" NAME="Lamey 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Lamey PJ, Rees TD, Binnie WH, Rankin KV. Mucous membrane pemphigoid. Treatment experience at two institutions. Oral Surg Oral Med Oral Pathol 1992;74(1):50-53.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lamey PJ, Rees TD, Binnie WH, Rankin KV</AU>
<TI>Mucous membrane pemphigoid. Treatment experience at two institutions</TI>
<SO>Oral Surgery, Oral Medicine, and Oral Pathology</SO>
<YR>1992</YR>
<VL>74</VL>
<NO>1</NO>
<PG>50-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Letko-2004" NAME="Letko 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Letko E, Miserocchi E, Daoud YJ, Christen W, Foster CS, Ahmed AR</AU>
<TI>A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies</TI>
<SO>Clinical Immunology (Orlando, Fla)</SO>
<YR>2004</YR>
<VL>111</VL>
<PG>303-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sami N, Letko E, Androudi S, Daoud Y, Foster CS, Ahmed AR</AU>
<TI>Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up</TI>
<SO>Ophthalmology</SO>
<YR>2004</YR>
<VL>111</VL>
<PG>1380-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luke-1999" MODIFIED="2008-06-18 11:00:50 +0100" MODIFIED_BY="Diane A  Horsley" NAME="Luke 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-06-18 11:00:50 +0100" MODIFIED_BY="Diane A  Horsley" NOTES="&lt;p&gt;Luke MC, Darling TN, Hsu R, et al. Mucosal morbidity in patients with epidermolysis bullosa acquisita. Arch Dermatol 1999;135(8):954-959.&lt;/p&gt;" NOTES_MODIFIED="2008-06-18 11:00:50 +0100" NOTES_MODIFIED_BY="Diane A  Horsley" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Luke MC, Darling TN, Hsu R, Summers RM, Smith JA, Solomon BI, et al</AU>
<TI>Mucosal morbidity in patients with epidermolysis bullosa acquisita</TI>
<SO>Archives of Dermatology</SO>
<YR>1999</YR>
<VL>135</VL>
<NO>8</NO>
<PG>954-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matthews-1989" NAME="Matthews 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Matthews RW, Pinkney RC, Scully C. The management of intransigent desquamative gingivitis with Dapsone. Ann Dent 1989;48(1):41-43.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Matthews RW, Pinkney RC, Scully C</AU>
<TI>The management of intransigent desquamative gingivitis with Dapsone</TI>
<SO>Annals of Dentistry</SO>
<YR>1989</YR>
<VL>48</VL>
<NO>1</NO>
<PG>41-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCluskey-2004" NAME="McCluskey 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McCluskey P, Chang JH, Singh R, Wakefield D</AU>
<TI>Methotrexate therapy for ocular cicatricial pemphigoid</TI>
<SO>Ophthalmology</SO>
<YR>2004</YR>
<VL>111</VL>
<PG>796-801</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McFadden-1989" NAME="McFadden 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;McFadden JP, Leonard JN, Powles AV, Rutman AJ, Fry L. Sulphamethoxypyridazine for dermatitis herpetiformis, linear IgA disease and cicatricial pemphigoid. Br J Dermatol 1989;121(6):759-762.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McFadden JP, Leonard JN, Powles AV, Rutman AJ, Fry L</AU>
<TI>Sulphamethoxypyridazine for dermatitis herpetiformis, linear IgA disease and cicatricial pemphigoid</TI>
<SO>British Journal of Dermatology</SO>
<YR>1989</YR>
<VL>121</VL>
<NO>6</NO>
<PG>759-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Megahed-1994" NAME="Megahed 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Megahed M, Scharffetter-Kochanek K. Epidermolysis bullosa acquisita - successful treatment with colchicine. Arch Dermatol Res 1994;286(1):35-46.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Megahed M, Scharffetter-Kochanek K</AU>
<TI>Epidermolysis bullosa acquisita - successful treatment with colchicine</TI>
<SO>Archives of Dermatological Research</SO>
<YR>1994</YR>
<VL>286</VL>
<NO>1</NO>
<PG>35-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mondino-1990" NAME="Mondino 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mondino BJ, Brown SI</AU>
<TI>Immunosuppressive therapy in ocular cicatricial pemphigoid</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1983</YR>
<VL>96</VL>
<NO>4</NO>
<PG>453-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Mondino BJ. Cicatricial pemphigoid and erythema multiforme. Ophthalmology 1990;97(7):939-952.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mondino BJ</AU>
<TI>Cicatricial pemphigoid and erythema multiforme</TI>
<SO>Ophthalmology</SO>
<YR>1990</YR>
<VL>97</VL>
<NO>7</NO>
<PG>939-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nayar-1993" NAME="Nayar 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Nayar M, Wojnarowska F. Cicatricial pemphigoid: a re-evaluation of therapy. J Dermatol Treat 1993;4:89-93.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nayar M, Wojnarowska F</AU>
<TI>Cicatricial pemphigoid: a re-evaluation of therapy</TI>
<SO>The Journal of Dermatological Treatment</SO>
<YR>1993</YR>
<VL>4</VL>
<PG>89-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poskitt-1995" NAME="Poskitt 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Poskitt L, Wojnarowska F. Minimizing cicatricial pemphigoid orodynia with minocycline. Br J Dermatol 1995;132:784-789.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Poskitt L, Wojnarowska F</AU>
<TI>Minimizing cicatricial pemphigoid orodynia with minocycline</TI>
<SO>British Journal of Dermatology</SO>
<YR>1995</YR>
<VL>132</VL>
<PG>784-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rappersberger-1988" NAME="Rappersberger 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Rappersberger K, Konrad K, Schenk P, Tappeiner G. [Acquired epidermolysis bullosa. A clinico-pathologic study]. Hautarzt 1988;39(6):355-362.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rappersberger K, Konrad K, Schenk P, Tappeiner G</AU>
<TI>[Acquired epidermolysis bullosa. A clinico-pathologic study]</TI>
<SO>Hautarzt</SO>
<YR>1988</YR>
<VL>39</VL>
<NO>6</NO>
<PG>355-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reiche-1998" NAME="Reiche 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Reiche L, Wojnarowska F, Mallon E. Combination therapy with nicotinamide and tetracyclines for cicatricial pemphigoid: further support for its efficacy. Clin Exp Dermatol 1998;23(6):254-7.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Reiche L, Wojnarowska F, Mallon E</AU>
<TI>Combination therapy with nicotinamide and tetracyclines for cicatricial pemphigoid: further support for its efficacy</TI>
<SO>Clinical and Experimental Dermatology</SO>
<YR>1998</YR>
<VL>23</VL>
<NO>6</NO>
<PG>254-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rogers-1982" NAME="Rogers 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Rogers RSd, Seehafer JR, Perry HO. Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. J Am Acad Dermatol 1982;6(2):215-223.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rogers RS III, Seehafer JR, Perry HO</AU>
<TI>Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone</TI>
<SO>Journal of American Academy of Dermatology</SO>
<YR>1982</YR>
<VL>6</VL>
<NO>2</NO>
<PG>215-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rogers RS</AU>
<TI>Dapsone and sulfapyridine therapy of pemphigoid diseases</TI>
<SO>Australasian Journal of Dermatology</SO>
<YR>1986</YR>
<VL>27</VL>
<NO>2</NO>
<PG>58-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rogers-1988" NAME="Rogers 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Rogers RSd, Mehregan DA. Dapsone therapy of cicatricial pemphigoid. Semin Dermatol 1988;7(3):201-205.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rogers RS III, Mehregan DA</AU>
<TI>Dapsone therapy of cicatricial pemphigoid</TI>
<SO>Seminars in Dermatology</SO>
<YR>1988</YR>
<VL>7</VL>
<NO>3</NO>
<PG>201-205</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Secchi-1996" NAME="Secchi 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Secchi AG, Tognon MS. Intraoperative mitomycin C in the treatment of cicatricial obliterations of conjunctival fornices. Am J Ophthalmol 1996;122(5):728-730.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Secchi AG, Tognon MS</AU>
<TI>Intraoperative mitomycin C in the treatment of cicatricial obliterations of conjunctival fornices</TI>
<SO>American Journal Ophthalmology</SO>
<YR>1996</YR>
<VL>122</VL>
<NO>5</NO>
<PG>728-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tauber-1991" NAME="Tauber 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Foster CS, Neumann R, Tauber J</AU>
<TI>Long-term results of systemic chemotherapy for ocular cicatricial pemphigoid</TI>
<SO>Documenta ophthalmologica. Advances in opthalmology</SO>
<YR>1992</YR>
<VL>82</VL>
<NO>3</NO>
<PG>223-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neumann R, Tauber J, Foster CS</AU>
<TI>Remission and recurrence after withdrawal of therapy for ocular cicatricial pemphigoid</TI>
<SO>Ophthalmology</SO>
<YR>1991</YR>
<VL>98</VL>
<NO>6</NO>
<PG>858-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Tauber J, Sainz de la Maza M, Foster CS. Systemic chemotherapy for ocular cicatricial pemphigoid [see comments]. Cornea 1991;10(3):185-195.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tauber J, Sainz de la Maza M, Foster CS</AU>
<TI>Systemic chemotherapy for ocular cicatricial pemphigoid [see comments]</TI>
<SO>Cornea</SO>
<YR>1991</YR>
<VL>10</VL>
<NO>3</NO>
<PG>185-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thornhill-2000" NAME="Thornhill 2000" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thornhill M, Pemberton M, Buchanan J, Theaker E</AU>
<TI>An open clinical trial of sulphamethoxypyridazine in the treatment of mucous membrane pemphigoid</TI>
<SO>The British Journal of Dermatology</SO>
<YR>2000</YR>
<VL>143</VL>
<NO>1</NO>
<PG>117-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vincent-1993" NAME="Vincent 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Vincent SD, Lilly GE, Baker KA. Clinical, historic, and therapeutic features of cicatricial pemphigoid. A literature review and open therapeutic trial with corticosteroids. Oral Surg Oral Med Oral Pathol 1993;76(4):453-459.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vincent SD, Lilly GE, Baker KA</AU>
<TI>Clinical, historic, and therapeutic features of cicatricial pemphigoid. A literature review and open therapeutic trial with corticosteroids</TI>
<SO>Oral Surgery, Oral Medicine and Oral Pathology</SO>
<YR>1993</YR>
<VL>76</VL>
<NO>4</NO>
<PG>453-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wright-1979" NAME="Wright 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Wright P. Enigma of ocular cicatricial pemphigoid. A comparative study of clinical and immunological findings. Trans Ophthalmol Soc U K 1979;99(1):141-145.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wright P</AU>
<TI>Enigma of ocular cicatricial pemphigoid. A comparative study of clinical and immunological findings</TI>
<SO>Transactions of the Ophthalmological Societies of the United Kingdom</SO>
<YR>1979</YR>
<VL>99</VL>
<NO>1</NO>
<PG>141-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Bernard-1995" NAME="Bernard 1995" NOTES="&lt;p&gt;Bernard P, Vaillant L, Labeille B, Bedane C, Arbeille B, Denoeux JP, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group [see comments]. Arch Dermatol 1995;131(1):48-52.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Bernard P, Vaillant L, Labeille B, Bedane C, Arbeille B, Denoeux JP, et al</AU>
<TI>Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group [see comments]</TI>
<SO>Archives of Dermatology</SO>
<YR>1995</YR>
<VL>131</VL>
<NO>(1)</NO>
<PG>48-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Borradori-1995" NAME="Borradori 1995" NOTES="&lt;p&gt;Borradori L, Caldwell JB, Briggaman RA, Burr CE, Gammon WR, James WD, et al. Passive transfer of autoantibodies from a patient with mutilating epidermolysis bullosa acquisita induces specific alterations in the skin of neonatal mice. Arch Dermatol 1995;131(5):590-5.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Borradori L, Caldwell JB, Briggaman RA, Burr CE, Gammon WR, James WD, et al</AU>
<TI>Passive transfer of autoantibodies from a patient with mutilating epidermolysis bullosa acquisita induces specific alterations in the skin of neonatal mice</TI>
<SO>Archives of Dermatology</SO>
<YR>1995</YR>
<VL>131</VL>
<NO>(5)</NO>
<PG>590-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Briggaman-1990" NAME="Briggaman 1990" NOTES="&lt;p&gt;Briggaman RA GWWD. Epidermolysis bullosa acquisita. In: RA WFB, editor. Management of blistering diseases. London: Chapman and Hall Medical; 1990. p. 127-38.&lt;/p&gt;" TYPE="BOOK_SECTION">
<AU>Briggaman RA, Gammon WR, Woodley DT</AU>
<TI>Epidermolysis bullosa acquisita</TI>
<SO>Management of blistering diseases</SO>
<YR>1990</YR>
<PG>127-38</PG>
<ED>Wojnarowska F, Briggaman RA</ED>
<PB>Chapman and Hall Medical</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chan-2002" NAME="Chan 2002" TYPE="JOURNAL_ARTICLE">
<AU>Chan LS, Ahmed AR, Anhalt GJ, et al</AU>
<TI>The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators</TI>
<SO>Archives of Dermatology</SO>
<YR>2002</YR>
<VL>138</VL>
<NO>3</NO>
<PG>370-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dragan-1999" NAME="Dragan 1999" TYPE="JOURNAL_ARTICLE">
<AU>Dragan L, Eng AM, Lam S, Persson T</AU>
<TI>Tetracycline and niacinamide: treatment alternatives in ocular cicatricial pemphigoid</TI>
<SO>Cutis</SO>
<YR>1999</YR>
<VL>63</VL>
<NO>3</NO>
<PG>181-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fine-1990" NAME="Fine 1990" NOTES="&lt;p&gt;J F. Cicatricial pemphigoid. In: RA WFB, editor. Management of blistering diseases. London: Chapman and Hall Medical; 1990. p. 83-92.&lt;/p&gt;" TYPE="BOOK_SECTION">
<AU>Fine J</AU>
<TI>Cicatricial pemphigoid</TI>
<SO>Management of blistering diseases</SO>
<YR>1990</YR>
<PG>83-92</PG>
<ED>Wojnarowska F, Briggaman RA</ED>
<PB>Chapman and Hall Medical</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fivenson-1994" NAME="Fivenson 1994" TYPE="JOURNAL_ARTICLE">
<AU>Fivenson D, Breneman D, Rosen G, Hersh C, Cardone S, Mutasim D</AU>
<TI>Nicotinamide and tetracycline therapy of bullous pemphigoid</TI>
<SO>Archives of Dermatology</SO>
<YR>1994</YR>
<VL>130</VL>
<NO>6</NO>
<PG>753-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gammon-1984" NAME="Gammon 1984" NOTES="&lt;p&gt;Gammon WR, Briggaman RA, Inman AOd, Queen LL, Wheeler CE. Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1.0 M sodium chloride-separated skin. J Invest Dermatol 1984;82(2):139-44.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Gammon WR, Briggaman RA, Inman AOd, Queen LL, Wheeler CE</AU>
<TI>Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1.0 M sodium chloride-separated skin</TI>
<SO>The Journal of Investigative Dermatology</SO>
<YR>1984</YR>
<VL>82</VL>
<NO>2</NO>
<PG>139-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gammon-1988" NAME="Gammon 1988" NOTES="&lt;p&gt;Gammon WR. Epidermolysis bullosa acquisita. Semin Dermatol 1988;7(3):218-24.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Gammon WR</AU>
<TI>Epidermolysis bullosa acquisita</TI>
<SO>Seminars in Dermatology</SO>
<YR>1988</YR>
<VL>7</VL>
<NO>(3)</NO>
<PG>218-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kirtschig-1998" NAME="Kirtschig 1998" NOTES="&lt;p&gt;Kirtschig G. [Autoantigens of cicatricial pemphigoid and their pathogenetic significance]. Hautarzt 1998;49(11):818-25.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kirtschig G</AU>
<TI>Autoantigens of cicatricial pemphigoid and their pathogenetic significance</TI>
<SO>Hautarzt</SO>
<YR>1998</YR>
<VL>49</VL>
<NO>11</NO>
<PG>818-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lazarova-1996" NAME="Lazarova 1996" NOTES="&lt;p&gt;Lazarova Z, Yee C, Darling T, Briggaman RA, Yancey KB. Passive transfer of anti-laminin 5 antibodies induces subepidermal blisters in neonatal mice. J Clin Invest 1996;98(7):1509-18.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Lazarova Z, Yee C, Darling T, Briggaman RA, Yancey KB</AU>
<TI>Passive transfer of anti-laminin 5 antibodies induces subepidermal blisters in neonatal mice</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>1996</YR>
<VL>98</VL>
<NO>7</NO>
<PG>1509-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liu-1993" NAME="Liu 1993" NOTES="&lt;p&gt;Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DJ, Fairley JA, et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 1993;92(5):2480-8.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DJ, Fairley JA, et al</AU>
<TI>A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180</TI>
<SO>The Journal of Clinical Investigation</SO>
<YR>1993</YR>
<VL>92</VL>
<NO>5</NO>
<PG>2480-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wojnarowska-1998" NAME="Wojnarowska 1998" NOTES="&lt;p&gt;F W. Cicatricial pemphigoid / Epidermolysis bullosa acquisita. In: Champion RH BJ, Burns DA &amp;amp; Breathnach SM, editor. Rook / Wilkinson /Ebling Textbook of Dermatology. Oxford: Blackwell science; 1998. p. 1873-7 &amp;amp; 1884-7.&lt;/p&gt;" TYPE="BOOK_SECTION">
<AU>Wojnarowska F, Eady RAJ, Burge SM</AU>
<TI>Bullous eruptions</TI>
<SO>Textbook of Dermatology</SO>
<YR>1998</YR>
<VL>3</VL>
<PG>1873-1877, 1884-7</PG>
<EN>6th</EN>
<ED>Champion RH, Burton JL, Burns DA &amp; Breathnach SM</ED>
<PB>Blackwell Science Ltd.</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zillikens-1995" NAME="Zillikens 1995" NOTES="&lt;p&gt;2002&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Zillikens D, Wever S, Roth A, Hashimoto T, Brocker EB</AU>
<TI>Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany [letter; comment]</TI>
<SO>Archives of Dermatology</SO>
<YR>1995</YR>
<VL>131</VL>
<NO>8</NO>
<PG>957-58</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES>
<REFERENCE ID="REF-Kirtschig-2002" NAME="Kirtschig 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kirtschig G, Murrell DM, Wojnarowska F, Khumalo N</AU>
<TI>Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review</TI>
<SO>Archives of Dermatology</SO>
<YR>2002</YR>
<VL>138</VL>
<NO>3</NO>
<PG>380-4</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-06-18 09:55:14 +0100" MODIFIED_BY="Diane A  Horsley">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-06-18 09:55:00 +0100" MODIFIED_BY="Diane A  Horsley" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-06-18 09:54:41 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Foster-1986a">
<CHAR_METHODS>
<P>Randomized; table of random numbers, "incomplete block design", were placed in sequentially numbered sealed envelopes. <BR/>double blind: a masked observer graded the disease activity; patients received either dextrose placebo + prednisone or cyclophosphamide + prednisone<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>24 patients with bilateral stage III ocular MMP (symblepharon formation) a: 12; b: 12 Evaluable: a: 12; b: 12</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-06-18 09:54:41 +0100" MODIFIED_BY="Diane A  Horsley">
<P>a: cyclophosphamide (2 mg/kg/day) plus prednisone (1 mg/kg/day)<BR/>b: prednisone (1 mg/kg/day)<BR/>(six months treatment)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Criteria for successful treatment: (1) abolition of all clinical signs of conjunctival inflammation, (2) absence of evidence indicating progression of subepithelial fibrosis/conjunctival cicatrization.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No drop outs, all patients completed the follow-up period</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-06-18 09:55:00 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Foster-1986b">
<CHAR_METHODS>
<P>Randomized, table of random numbers, "incomplete block design", were placed in sequentially numbered sealed envelopes.<BR/>double blind (same design as trial 1)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>40 patients with stage III ocular MMP (symblepharon formation)<BR/>a: 20; b: 20<BR/>Evaluable:<BR/>a: 20; b:20</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-06-18 09:55:00 +0100" MODIFIED_BY="Diane A  Horsley">
<P>a: dapsone (2 mg/kg/day)<BR/>b: cyclophosphamide (2 mg/kg/day)<BR/>the use of prednisone is not clearly stated; additional information via trial author: all patients usually receive prednisone in the beginning of the treatment</P>
<P>(six months treatment)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Same criteria as above</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No drop outs, all patients completed the follow-up period</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<BR/>Add definitions of any other abbreviations used.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-06-18 09:55:14 +0100" MODIFIED_BY="Diane A  Horsley" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Arpey-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Axt-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bialasiewicz-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Callot_x002d_Mellot-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carbone-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carrozzo-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cunningham-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Donnenfeld-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Edwards-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Elder-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Elder-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fern-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Foster-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised, prospective, controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Foster-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Francis-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gillies-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gonzalez_x002d_Moles-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>A descriptive pre-test/post-test clinical study without control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gordon-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gupta-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hanson-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Harman-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ingen_x002d_Housz-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lamey-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-18 09:55:14 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-Letko-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-18 09:55:14 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Non randomised comparison between intravenous immunoglobulin and conventional immunosuppressive therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Luke-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Matthews-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-18 09:36:01 +0100" MODIFIED_BY="Diane A  Horsley" STUDY_ID="STD-McCluskey-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-18 09:36:01 +0100" MODIFIED_BY="Diane A  Horsley">
<P>Retrospective, non comparative, interventional case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McFadden-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Megahed-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mondino-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nayar-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Poskitt-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rappersberger-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reiche-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rogers-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rogers-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Secchi-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tauber-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thornhill-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vincent-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wright-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Foster-1986a">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Foster-1986b">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-06-18 10:18:23 +0100" MODIFIED_BY="Diane A  Horsley">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-06-18 09:58:23 +0100" MODIFIED_BY="Diane A  Horsley" NO="1">
<TITLE>Childhood EBA: Nonrandomised studies</TITLE>
<TABLE COLS="5" ROWS="4">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>N of participants</P>
</TH>
<TH>
<P>Treatments</P>
</TH>
<TH>
<P>Results</P>
</TH>
<TH>
<P>Conclusions</P>
</TH>
</TR>
<TR>
<TD>
<P>Arpey 1991</P>
</TD>
<TD>
<P>three</P>
</TD>
<TD>
<P>Systemic v topical: 40 mg prednisolone/day + 50 mg dapsone (n = 1); topical steroids (n = 2)</P>
</TD>
<TD>
<P>improvement with prednisolone+dapsone; no response or spontaneous remission with topical steroids</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Callot-Mellot 1997</P>
</TD>
<TD>
<P>three</P>
</TD>
<TD>
<P>1.8 mg/kg/day prednisolone + 2 mg/kg/day dapsone+oral and systemic antimicrobials; 1 mg/kg/day prednisone + 1 mg/kg/day dapsone</P>
</TD>
<TD>
<P>remission after two years with prednisolone+dapsone+antimicrobials; resolution of blisters after two days with prednisone+dapsone (wrong diagnosis?)</P>
</TD>
<TD>
<P>dapsone and prednisone may be beneficial</P>
</TD>
</TR>
<TR>
<TD>
<P>Edwards 1998</P>
</TD>
<TD>
<P>five</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>dapsone may be beneficial</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2008-06-18 10:04:29 +0100" MODIFIED_BY="Diane A  Horsley" NO="2">
<TITLE>EBA: Nonrandomised studies</TITLE>
<TABLE COLS="6" ROWS="8">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>N of participants</P>
</TH>
<TH>
<P>Treatments</P>
</TH>
<TH>
<P>Results</P>
</TH>
<TH>
<P>Conclusions</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<TR>
<TD>
<P>Cunningham 1996</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>colchicine with or without other treatments (n = 4); remaining 10 participants could not tolerate colchicine (diarrhoea) or failed to improve or had contraindications (inflammatory bowel disease)</P>
</TD>
<TD>
<P>0.5 to 1 mg/day colchicine+initially prednisone = improvement after 2 weeks (n = 1); 0.6 to 1.2 mg/day colchicine, subsequently additional dapsone = improvement (n = 1); 0.5 to 2 mg/day colchicine + 1 mg/kg/day prednisone, sulfapyridine, azathioprine = improvement after 4 months (n = 1); 0.5 to 1.5 mg/day colchicine = improvement after 2 months, but recurrence after 4 years (n = 1)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Gordon 1997</P>
</TD>
<TD>
<P>three</P>
</TD>
<TD>
<P>1 to 1.5 mg/kg 8-methoxypsoralen prior to leukapheresis (6 to 7 cycles)</P>
</TD>
<TD>
<P>two participants improved, one did not</P>
</TD>
<TD>
<P>some benefit with 8-methoxypsoralen and leukapheresis</P>
</TD>
<TD>
<P>interim results for study of ten participants</P>
</TD>
</TR>
<TR>
<TD>
<P>Gupta 1990</P>
</TD>
<TD>
<P>two</P>
</TD>
<TD>
<P>6 mg/kg/day cyclosporine (for 30 weeks?)</P>
</TD>
<TD>
<P>improvement after two to four weeks</P>
</TD>
<TD>
<P>systemic cylosporine of some benefit</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Harman 1999</P>
</TD>
<TD>
<P>two</P>
</TD>
<TD>
<P>0.4 g/kg i.v. immunoglobulins for 5 days</P>
</TD>
<TD>
<P>slow improvement after 17 courses (n = 1); rapid response after 6 courses (n = 1)</P>
</TD>
<TD>
<P>some benefit of i.v. immunoglobulins</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Luke 1999</P>
</TD>
<TD>
<P>4+</P>
</TD>
<TD>
<P>60 mg/day prednisolone + 200 mg/day dapsone; 2.5 to 4 mg/kg/day cyclosporine + 101 to 20 mg/day prednisone</P>
</TD>
<TD>
<P>prednisolone+dapsone - good response (n = 1); cyclosporine+prednisone - little benefit (n = 1); no detailed information (n = 2); topical steroids and surgery, daclizumab (a humanized monoclonal antibody directed against the interleukin 2 receptor) were of no benefit (n not specified)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Megahed 1994</P>
</TD>
<TD>
<P>two</P>
</TD>
<TD>
<P>2 mg/day colchicine</P>
</TD>
<TD>
<P>improvement after two weeks</P>
</TD>
<TD>
<P>some benefit with colchicine</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Rappersberger 1988</P>
</TD>
<TD>
<P>three</P>
</TD>
<TD>
<P>100 mg/day dapsone (n = 1); 200 mg/day dapsone + 200 mg/day methylprednisolone (n = 1); 16 mg/day methylprednisone+topical steroids+antibiotics</P>
</TD>
<TD>
<P>dapsone - improvement (n = 1); dapsone+methylprednisone - slow improvement (n = 1); methylpredisone+topical steroids+antibiotics - improvement (n = 1)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2008-06-18 10:18:23 +0100" MODIFIED_BY="Diane A  Horsley" NO="3">
<TITLE>MMP: Nonrandomised studies</TITLE>
<TABLE COLS="6" ROWS="32">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>N of participants</P>
</TH>
<TH>
<P>Treatments</P>
</TH>
<TH>
<P>Results</P>
</TH>
<TH>
<P>Conclusions</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<TR>
<TD>
<P>Axt 1995</P>
</TD>
<TD>
<P>six generalised MMP</P>
</TD>
<TD>
<P>500 mg/day i.v. cyclophosphamide + 100 mg/day i.v. dexamethasone pulse</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>no major effect of cyclophosphamide and dexamethasone pulse therapy in ocular disease</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Bialasiewicz 1994</P>
</TD>
<TD>
<P>nine ocular MMP (all with symblepharon?)</P>
</TD>
<TD>
<P>125 to 150 mg/day azathioprione+nasal mucosal graft</P>
</TD>
<TD>
<P>At 15 months follow-up, pain relief in all, recurrence of symblepharon in 2/9?</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carbone 1998</P>
</TD>
<TD>
<P>six oral MMP</P>
</TD>
<TD>
<P>50 to 100 mg/day prednisone for 38.5 days on average</P>
</TD>
<TD>
<P>2/6 complete remission; 4/6 partial remission</P>
</TD>
<TD>
<P>some participants benefited from systemic corticosteroids</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Carrozzo 1997</P>
</TD>
<TD>
<P>eight oral MMP</P>
</TD>
<TD>
<P>topical clobetasol propionate</P>
</TD>
<TD>
<P>4/8 complete remission after 5.7 months on average</P>
</TD>
<TD>
<P>some participants benefited from topical corticosteroids</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Donnenfeld 1999</P>
</TD>
<TD>
<P>nine ocular MMP</P>
</TD>
<TD>
<P>subconjunctival mitomycin C in one eye (second eye served as control) - one dose of 0.1 mg</P>
</TD>
<TD>
<P>At 12 to 40 months follow-up, 8/9 treated eyes showed no progression, one required additional cyclophosphamide; 5/9 untreated eyes showed progression</P>
</TD>
<TD>
<P>some participants benefited from mitomycin C</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Elder 1995</P>
</TD>
<TD>
<P>10 ocular MMP (19 eyes)</P>
</TD>
<TD>
<P>1.5 mg cyclophosphamide (8.7 months treatment and follow-up one average) + 60 mg/day prednisolone (6 months); 6 participants had failed to respond to sulfa drugs</P>
</TD>
<TD>
<P>Inflammation resolved in 15/18 eyes after 2.4 months, 2/18 eyes perforated, 4/18 eyes showed progression of scarring</P>
</TD>
<TD>
<P>participants with severe ocular disease benefit from cyclophosphamide and systemic corticosteroids</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Elder 1996</P>
</TD>
<TD>
<P>20 ocular MMP</P>
</TD>
<TD>
<P>1000 mg/day sulphapyridine; 8 participants had additional topical treatment</P>
</TD>
<TD>
<P>10/20 (22/39 eyes) responded after 2 months at the latest</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Fern 1992</P>
</TD>
<TD>
<P>five ocular MMP</P>
</TD>
<TD>
<P>100 to 150 mg/day dapsone</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>dapsone beneficial in acute inflammatory disease, but not in scarring MMP</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Foster 1982</P>
</TD>
<TD>
<P>26 ocular MMP</P>
</TD>
<TD>
<P>cyclophosphamide 1 to 2 mg/kg/day + prednisone (n = 18); 80(?) to 20 mg/day (n = 2); control (non-systemic treatment) n = 6</P>
</TD>
<TD>
<P>cyclophosphamide: 14/14 beneficial (adverse effects: leukopenia, alopecia, anaemia, haemorrhagic cystitis); 3/18 withdrew because of gastrointestinal upset; prednisone - 2/2 progression of disease; controls - 6/6 progression of disease</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Foster 1999</P>
</TD>
<TD>
<P>ten ocular MMP</P>
</TD>
<TD>
<P>2 to 3 g immunoglobulins/kg/cycle (19 cycles in 18 months)</P>
</TD>
<TD>
<P>response seen between a minimum of 4 and a maximum of 12 cycles; inflammation improved in 10/10; all 10 still receiving at time article was written</P>
</TD>
<TD>
<P>i.v. immunoglobulins beneficial</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Francis 1990</P>
</TD>
<TD>
<P>eight ocular MMP</P>
</TD>
<TD>
<P>50 mg/day prednisolone + 1.5 to 2 mg/kg/day cyclophosphamide (n = 2); 5 to 15 mg/week methotrexate (n = 6)</P>
</TD>
<TD>
<P>7/8 showed improvement (not specified what sort and which regimen)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Gillies 1996</P>
</TD>
<TD>
<P>five ocular MMP, symblepharon (ten eyes)</P>
</TD>
<TD>
<P>interferon alpha 2-b injection into one conjunctiva (worst eye), second eye served as control</P>
</TD>
<TD>
<P>3/5 treated eyes improved, 2/5 were unchanged; the 5 untreated eyes showed no progression</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Gonzalez-Moles 2003</P>
</TD>
<TD>
<P>22 oral MMP [and 11 oral lichen planus]</P>
</TD>
<TD>
<P>0.05% clobetasol propionate plus 100,000 IU/cc of nystatin in orabase paste in gingival trays (applied for 5 mins 3 times daily, the reduced to alternate days with complete or excellent response, then gradual further reduction to 1 5 min application on alternate days depending on clinical response)</P>
</TD>
<TD>
<P>all 22 showed a complete pain response after 8 weeks of treatment and this was maintained for the 48 week follow-up; other results were not reported separately for MMP and oral lichen planus. No adverse effects were observed.</P>
</TD>
<TD>
<P>This method of topical steroid application in the mouth may be a treatment worth considering in a future RCT</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Hanson 1988</P>
</TD>
<TD>
<P>142 generalized MMP</P>
</TD>
<TD>
<P>125 to 150 mg/day dapsone first choice treatment (second choice corticosteroids, azathioprine, cyclophosphamide)</P>
</TD>
<TD>
<P>beneficial in most participants, no further details of treatment given (focuses on aerodigestive tract manifestations of MMP)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Ingen-Housz 2005</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>1.5 to 2 mg MMF daily (depending on body weight): 7 participants with severe MMP received MMF after i.v. bolus treatment with cyclophosphamide; 3 participants with severe MMP who experienced a recurrence after cessation of cyclophosphamide treatment; 4 participants with moderate MMP who received MMP as their primary intervention; (all or most of the participants may have received additional treatment with dapsone (max. 2 mg/kg/day) while being treated with MMF)</P>
</TD>
<TD>
<P>MMF after cyclophosphamide bolus - MMP controlled (n = 3), some benefit (n = 2), no effect (n = 2); recurrence after ceasing cyclophosphamide - 2 participants went into remission on MMF, disease progression in 1; MMF as primary intervention - 3 participants went into remission, progression was seen in 1 (and cyclophosphamide was started); overall MMF helped control disease in 10/14, no stabilising effect seen in 4 participants: Adverse effects - MMF was well tolerated in 13/14 participants, 1 had pancytopaenia and gastrointestinal effects</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>direct IF and immunoelectron microscopy proven MMP</P>
</TD>
</TR>
<TR>
<TD>
<P>Lamey 1992</P>
</TD>
<TD>
<P>50 oral MMP</P>
</TD>
<TD>
<P>topical corticosteroids versus systemic treatment</P>
</TD>
<TD>
<P>topical fluocinonide (n = 19) - 3 improved, 16 asymptomatic; topical fluocinonide+other topicals (n = 11) - 3 improved, 8 asymptomatic; prednisolone+topicals (n = 14) - 5 improved, 8 asymptomatic (1 unchanged); azathioprine+prednisolone (n =3 ) - 0 improved, 3 asymptomatic; dapsone+topicals (n = 2) - 1 improved, 1 asymptomatic; cyclophosphamide+prednisolone (n = 1) - asymptomatic</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Letko 2004</P>
</TD>
<TD>
<P>16 ocular MMP (all stage 2)</P>
</TD>
<TD>
<P>intravenous immunoglobulin (IVIg) versus conventional immunopressive therapies: IVIg - started at 2 g/kg initially at 2 to 4 week intervals, then prior systemic conventional therapy discontinued and when clinical improvement was observed, the interval between infusion cycles was increased until a 16 week interval was reached; conventional immunosuppressive therapy included dapsone, methotrexate, azathioprine, mycophenolate mofetil, cyclophosphamide, prednisone)</P>
</TD>
<TD>
<P>8/8 participants in the IVIg group had not progressed from stage 2 ocular MMP after a mean treatment period of 24 months; 4/8 participants in the conventional immunosuppression group had progressed from stage 2 to stage 3, and 4 were stable at stage 2 after a mean treatment period of 45 months: Adverse effects - 4 IVIg participants had drug-related headaches or nausea, which resolved when the rate of infusions was decreased; all participants in the conventional immunosuppression group show multiple drug related effects (anaemia, fatigue, leukopenia, osteoporosis, infection)</P>
</TD>
<TD>
<P>Authors recommend a RCT to confirm the results and determine the optimal protocol</P>
</TD>
<TD>
<P>diagnosis of MMP confirmed by IF; selection to IVIg treatment dependent on financial support from insurance company; all participants received immunopressive treatment before IVIg</P>
</TD>
</TR>
<TR>
<TD>
<P>Matthews 1989</P>
</TD>
<TD>
<P>seven oral MMP (five completed)</P>
</TD>
<TD>
<P>75 mg dapsone for 3 months</P>
</TD>
<TD>
<P>3/5 some improvement, 2/5 no benefit; 2/7 withdrew from trial because of adverse effects (headache, nausea)</P>
</TD>
<TD>
<P>some participants benefited from dapsone</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>McCluskey 2004</P>
</TD>
<TD>
<P>17 (12 ocular MMP, 5 drug induced ocular MMP</P>
</TD>
<TD>
<P>oral methotrexate at a starting dose of 5 to 15 mg; 3 participants were pretreated with dapsone; ocular surface inflammation, mechanical trichiasis and blepharitis were treated aggressively with topical antibiotics, systemic doxycycline, topical steroids (n = 7), ocular lubrications and epilation; methotrexate dose was then adjusted according to clinical response and presence of adverse effects (5 to 25 mg a week); 5 mg folic acid was given on alternate days to reduce the risk of adverse effects</P>
</TD>
<TD>
<P>Mean methotrexate treatment of 15 months prevented progression of conjunctival cicatrisation in 12/17 (26 out of 34 eyes); 11/34 eyes had improved visual acuity, 18 maintained their pretreatment visual acuity; 5 eyes deteriorated</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>IF confirmed diagnosis (n=4)</P>
</TD>
</TR>
<TR>
<TD>
<P>McFadden 1989</P>
</TD>
<TD>
<P>15 oral and generalised MMP</P>
</TD>
<TD>
<P>500 to 1500 mg sulphamethoxypyridazine (SMXP)</P>
</TD>
<TD>
<P>MMP controlled (n = 1); effective in 10/15; controlled with dapsone and SMXP (n = 1); no response to combination (n = 13); adverse effect - allergic alveolitis (n = 1) - can be life threatening</P>
</TD>
<TD>
<P>some benefit from sulfa drugs</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Mondino 1990</P>
</TD>
<TD>
<P>139 ocular MMP</P>
</TD>
<TD>
<P>5 treatment modalities - control (n = 35); 1.5 mg/kg/day cyclophosphamide + 20 mg/day prednisone (n = 17); 1.5 mg/kg/day cyclophosphamide (n = 13); 1.5 mg/kg/day azathioprine (n = 10); 60 to 80 mg/day prednisone (n = 11); combined treatments (n = 51)</P>
</TD>
<TD>
<P>controls: progression in 40% of stage 1, 62% stage 2, 73% stage 3; cyclophos+pred: 17% stage 1, 21% stage 2, 25% stage 3; cyclophos: 25% stage 1, 10% stage 2, 75% stage 3; azathioprine: 33% stage 1, 56% stage 2, 50% stage 3; prednisone: 0% stage 1, 14% stage 2, 53% stage 3; combination: 14% stage 1, 24% stage 2, 53% stage 3</P>
</TD>
<TD>
<P>non-treated controls seem to have more progression</P>
</TD>
<TD>
<P>stage 0: no conjunctival shrinkage; stage 1: up to 25 % shrinkage of conjunctival fornices; stage 2: 25 % to 50 % conjunctival shrinkage; stage 3: about 75 % conjunctival shrinkage; stage 4: obliteration of conjunctival fornices with keratinization of ocular surface</P>
</TD>
</TR>
<TR>
<TD>
<P>Nayar 1993</P>
</TD>
<TD>
<P>48 generalised MMP</P>
</TD>
<TD>
<P>40 to 60 mg/day prednisolone (n = 15); 50 to 150 mg/day dapsone (n = 14); 100 to 150 mg azathioprine (n = 9); 50 to100 mg/day minocycline (n = 10)</P>
</TD>
<TD>
<P>prednisolone: beneficial in 5/15, no good effect for oral lesions; dapsone: beneficial in 7/14, oral and ocular lesions also improved; azathioprine: some benefit for cutaneous lesions in 6/9; minocycline: beneficial for oral lesions in 2/10, no effect in ocular inflammation</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>in all groups additional topical or low dose oral corticosteroids may have been used</P>
</TD>
</TR>
<TR>
<TD>
<P>Poskitt 1995</P>
</TD>
<TD>
<P>seven generalised MMP</P>
</TD>
<TD>
<P>50 to 100 mg/day minocycline</P>
</TD>
<TD>
<P>symptomatic improvement in 6/7 after 2 to 3 months treatment (average treatment duration 10 months)</P>
</TD>
<TD>
<P>in particular, those with orodynia benefited</P>
</TD>
<TD>
<P>all were started on minocycline because of failing to respond to previous treatment or due to adverse effects with previous treatment; some may have had additional systemic corticosteroid therapy</P>
</TD>
</TR>
<TR>
<TD>
<P>Reiche 1998</P>
</TD>
<TD>
<P>eight oral and generalised MMP</P>
</TD>
<TD>
<P>50 to 100 mg/day minocycline + 2.5 to 3 g/day nicotinamide</P>
</TD>
<TD>
<P>5/8 participants improved (treatment effect judged at 9 months)</P>
</TD>
<TD>
<P>some benefit from oral tetracyclines and nicotinamide</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Rogers 1982</P>
</TD>
<TD>
<P>24 oral and ocular MMP</P>
</TD>
<TD>
<P>75 to 200 mg/day dapsone</P>
</TD>
<TD>
<P>complete control (n = 11) or partial control of inflammation within 2 to 12 weeks (n = 19 total for complete and partial?); dapsone stopped in 8/24, because of disease remission (n = 2), no effect of dapsone, adverse effects (anaemia, rash) (n = 4)</P>
</TD>
<TD>
<P>some benefit from dapsone</P>
</TD>
<TD>
<P>15/24 had other treatment prior to dapsone</P>
</TD>
</TR>
<TR>
<TD>
<P>Rogers 1988</P>
</TD>
<TD>
<P>77 oral, ocular, generalised MMP</P>
</TD>
<TD>
<P>150 mg/day dapsone or 1500 to 3000 mg/day sulfapyridine (for a minimum of 12 weeks)</P>
</TD>
<TD>
<P>localised oral disease (n = 16) - 0 grade 0 [no improvement], 1 grade 1 [improvement but active disease], 3 grade 2 [major reduction of disease activity], 12 grade 3 [minimal to nil activity]; generalised MMP (no ocular) (n = 31) - 10? grade 0, 0 grade 1, 1 grade 2, 20 grade 3; ocular (n = 30) - 5? grade 0, 0 grade 1, 1 grade 2, 24 grade 3: follow-ip ranged from 1 to 12 years, with a mean of 4.3 years for localised oral MMp and 5.3 years for combined MMP and ocular MMP</P>
</TD>
<TD>
<P>some benefit from sulfa drugs</P>
</TD>
<TD>
<P>follow-up of Rogers 1982</P>
</TD>
</TR>
<TR>
<TD>
<P>Secchi 1996</P>
</TD>
<TD>
<P>four ocular MMP</P>
</TD>
<TD>
<P>0.4 mg/ml topical mitomycin C (intraoperative after synechiolysis)</P>
</TD>
<TD>
<P>beneficial in 4/4, no recurrence after a follow-up of 12 to 19 months</P>
</TD>
<TD>
<P>benefit from topical mitomycin C</P>
</TD>
<TD>
<P>participants had no active disease for at least six months before surgery (all eyes were free of inflammatory signs)</P>
</TD>
</TR>
<TR>
<TD>
<P>Thornhill 2000</P>
</TD>
<TD>
<P>25 oral MMP</P>
</TD>
<TD>
<P>1 g sulphamethoxypyridazine</P>
</TD>
<TD>
<P>beneficial 16/25, 6/25 still on treatment, 3/25 withdrawn due to side effects</P>
</TD>
<TD>
<P>benefit from SMXP in most patients</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Tauber 1991</P>
</TD>
<TD>
<P>117 ocular MMP</P>
</TD>
<TD>
<P>dapsone versus cyclophosphamide versus azathioprine: initially 2 mg/kg/day dapsone (additional prednisone in 8) (n = 69); initially 2 mg/kg/day cyclophosphamide (additional prednisone in 23?) (n = 25); initially 2 mg/kg/day azathioprine (additional prednisone in 2?) (n = 23)</P>
</TD>
<TD>
<P>By the end of follow-up (3 to 135 months, average 35 months), 81% had dapsone, 34% cyclophosphamide, 49% azathioprine; no significant differences were observed comparing progression rates</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Vincent 1993</P>
</TD>
<TD>
<P>19 oral MMP</P>
</TD>
<TD>
<P>oral versus topical steroids; topical triamcinolone 0.1 % to 0.5 % aqueous rinse (n = 11); 40 mg/day prednisolone for 5 days, 20 mg/day for 10 days (n = 4); topical and oral corticosteroids (n = 2); treatment not stated (n = 2)</P>
</TD>
<TD>
<P>triamcinolone - 10/11 required subsequent systemic steroid burst for disease control; prednisolone - results not stated; topical and oral corticosteroids - results not stated</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wright 1979</P>
</TD>
<TD>
<P>22 ocular MMP</P>
</TD>
<TD>
<P>topical versus systemic treatment: very potent topical steroids (n = 19) "some of these" with acute ulceration were treated with 60 to 120 mg/day prednisone; 100 mg/day azathioprine+topical steroids (n = 3)</P>
</TD>
<TD>
<P>no detailed results given</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-06-17 15:28:28 +0100" MODIFIED_BY="Cathy Bennett">
<COMPARISON ID="CMP-001" MODIFIED="2008-06-17 15:28:28 +0100" MODIFIED_BY="Cathy Bennett" NO="1">
<NAME>cyclophosphamide v other treatments</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="32" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="32" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>clinical improvement, short term (at 3 or 6 months)</NAME>
<GROUP_LABEL_1>cyclophos.</GROUP_LABEL_1>
<GROUP_LABEL_2>other treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours other</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cyclophos.</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="5" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>cyclophosphamide+prednisone v prednisone alone for 6 months</NAME>
<DICH_DATA CI_END="4.3275736461243675" CI_START="1.1935762805155752" EFFECT_SIZE="2.272727272727273" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.6362444673812325" LOG_CI_START="0.07685017964639275" LOG_EFFECT_SIZE="0.35654732351381263" ORDER="1" O_E="0.0" SE="0.32859097366182777" STUDY_ID="STD-Foster-1986a" TOTAL_1="12" TOTAL_2="12" VAR="0.10797202797202798" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="14" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>cyclophosphamide v dapsone for 3 months</NAME>
<DICH_DATA CI_END="1.8970926050149208" CI_START="1.053618012148746" EFFECT_SIZE="1.4137931034482758" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="14" LOG_CI_END="0.2780885311339763" LOG_CI_START="0.022683186507582456" LOG_EFFECT_SIZE="0.1503858588207794" ORDER="2" O_E="0.0" SE="0.15002636371038966" STUDY_ID="STD-Foster-1986b" TOTAL_1="20" TOTAL_2="20" VAR="0.022507909808162127" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-06-17 15:28:28 +0100" MODIFIED_BY="Cathy Bennett" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="205.84727468480568" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="388" TOTAL_2="388" WEIGHT="0.0" Z="0.0">
<NAME>adverse effects</NAME>
<GROUP_LABEL_1>cyclophosphamide</GROUP_LABEL_1>
<GROUP_LABEL_2>other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cyclophos</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="0" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>alopecia: cyclophos+pred versus pred</NAME>
<DICH_DATA CI_END="322.27833006975027" CI_START="1.3683824162318179" EFFECT_SIZE="21.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.508231104620231" LOG_CI_START="0.1362074848476075" LOG_EFFECT_SIZE="1.3222192947339193" ORDER="3" O_E="0.0" SE="1.3933384159607247" STUDY_ID="STD-Foster-1986a" TOTAL_1="12" TOTAL_2="12" VAR="1.9413919413919414" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>alopecia (severe): cyclophos+pred versus pred</NAME>
<DICH_DATA CI_END="67.05568402675195" CI_START="0.13421680996363317" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8264355970545303" LOG_CI_START="-0.8721930876152056" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="4" O_E="0.0" SE="1.585187847802434" STUDY_ID="STD-Foster-1986a" TOTAL_1="12" TOTAL_2="12" VAR="2.5128205128205123" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="0" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>anaemia: cyclophos+pred versus pred</NAME>
<DICH_DATA CI_END="379.5667070986592" CI_START="1.6466143850639305" EFFECT_SIZE="25.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="2.5792881121919318" LOG_CI_START="0.2165919051521431" LOG_EFFECT_SIZE="1.3979400086720377" ORDER="5" O_E="0.0" SE="1.3878594475500199" STUDY_ID="STD-Foster-1986a" TOTAL_1="12" TOTAL_2="12" VAR="1.926153846153846" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>haematuria: cyclophos+pred versus pred</NAME>
<DICH_DATA CI_END="67.05568402675195" CI_START="0.13421680996363317" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8264355970545303" LOG_CI_START="-0.8721930876152056" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="6" O_E="0.0" SE="1.585187847802434" STUDY_ID="STD-Foster-1986a" TOTAL_1="12" TOTAL_2="12" VAR="2.5128205128205123" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.02.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>haematuria: cyclophos versus dapsone</NAME>
<DICH_DATA CI_END="97.99788802329087" CI_START="0.2551075385834674" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.991216716205615" LOG_CI_START="-0.5932767075335774" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="7" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Foster-1986b" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-001.02.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>hypertension: cyclophos+pred versus pred</NAME>
<DICH_DATA CI_END="2.4988165463450835" CI_START="0.008167131474760041" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.39773437303938103" LOG_CI_START="-2.087930453067895" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="8" O_E="0.0" SE="1.4600918230947433" STUDY_ID="STD-Foster-1986a" TOTAL_1="12" TOTAL_2="12" VAR="2.1318681318681314" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>hypertension: cyclophos versus dapsone</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9" O_E="0.0" SE="0.0" STUDY_ID="STD-Foster-1986b" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.02.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>diabetes: cyclophos+pred versus pred</NAME>
<DICH_DATA CI_END="3.773467029338969" CI_START="0.010600331124930263" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5767405596967805" LOG_CI_START="-1.974680568368818" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="10" O_E="0.0" SE="1.4987174003640065" STUDY_ID="STD-Foster-1986a" TOTAL_1="12" TOTAL_2="12" VAR="2.2461538461538457" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>diabetes: cyclophos versus dapsone</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="11" O_E="0.0" SE="0.0" STUDY_ID="STD-Foster-1986b" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.02.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>osteoporosis: cyclophos+pred versus pred</NAME>
<DICH_DATA CI_END="3.773467029338969" CI_START="0.010600331124930263" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5767405596967805" LOG_CI_START="-1.974680568368818" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="12" O_E="0.0" SE="1.4987174003640065" STUDY_ID="STD-Foster-1986a" TOTAL_1="12" TOTAL_2="12" VAR="2.2461538461538457" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="11" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>osteoporosis: cyclophos versus dapsone</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="13" O_E="0.0" SE="0.0" STUDY_ID="STD-Foster-1986b" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-001.02.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="12" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>peptic ulcer: cyclophos+pred versus pred</NAME>
<DICH_DATA CI_END="1.8618417912803553" CI_START="0.006630895852786598" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2699427743396819" LOG_CI_START="-2.1784277932183316" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="14" O_E="0.0" SE="1.4381849910133495" STUDY_ID="STD-Foster-1986a" TOTAL_1="12" TOTAL_2="12" VAR="2.068376068376068" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="13" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>peptic ulcer: cyclophos versus dapsone</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15" O_E="0.0" SE="0.0" STUDY_ID="STD-Foster-1986b" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="14" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>abdominal: cyclophos+pred verus pred</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16" O_E="0.0" SE="0.0" STUDY_ID="STD-Foster-1986a" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.02.15" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="15" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>abdominal: cyclophos versus dapsone</NAME>
<DICH_DATA CI_END="3.919915520931636" CI_START="0.0102043015433387" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5932767075335775" LOG_CI_START="-1.991216716205615" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="17" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Foster-1986b" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-001.02.16" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="16" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>myopathy: cyclophos+pred versus pred</NAME>
<DICH_DATA CI_END="2.4988165463450835" CI_START="0.008167131474760041" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.39773437303938103" LOG_CI_START="-2.087930453067895" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="18" O_E="0.0" SE="1.4600918230947433" STUDY_ID="STD-Foster-1986a" TOTAL_1="12" TOTAL_2="12" VAR="2.1318681318681314" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.17" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="17" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>myopathy: cyclophos versus dapsone</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="19" O_E="0.0" SE="0.0" STUDY_ID="STD-Foster-1986b" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.02.18" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="18" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>psychosis: cyclophos+pred versus pred</NAME>
<DICH_DATA CI_END="3.773467029338969" CI_START="0.010600331124930263" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5767405596967805" LOG_CI_START="-1.974680568368818" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="20" O_E="0.0" SE="1.4987174003640065" STUDY_ID="STD-Foster-1986a" TOTAL_1="12" TOTAL_2="12" VAR="2.2461538461538457" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.19" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="19" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>psychosis: cyclophos versus dapsone</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21" O_E="0.0" SE="0.0" STUDY_ID="STD-Foster-1986b" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.20" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="20" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>nausea: cyclophos+pred versus pred</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="22" O_E="0.0" SE="0.0" STUDY_ID="STD-Foster-1986a" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-001.02.21" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="21" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>nausea: cyclophos versus dapsone</NAME>
<DICH_DATA CI_END="1.9371598241474748" CI_START="0.006373082312802401" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2871654533891674" LOG_CI_START="-2.195650472267817" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="23" O_E="0.0" SE="1.4584183648679576" STUDY_ID="STD-Foster-1986b" TOTAL_1="20" TOTAL_2="20" VAR="2.1269841269841274" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.22" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="22" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>hepatitis: cyclophos+pred versus pred</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24" O_E="0.0" SE="0.0" STUDY_ID="STD-Foster-1986a" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.02.23" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="23" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>hepatitis: cyclophos versus dapsone</NAME>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="25" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Foster-1986b" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.24" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="24" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>neuropathy: cyclophos+pred versus pred</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="26" O_E="0.0" SE="0.0" STUDY_ID="STD-Foster-1986a" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.02.25" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="25" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>neuropathy: cyclophos versus dapsone</NAME>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="27" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Foster-1986b" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-06-17 14:17:03 +0100" MODIFIED_BY="Cathy Bennett">
<APPENDIX ID="APP-01" MODIFIED="2008-06-17 14:09:03 +0100" MODIFIED_BY="Cathy Bennett" NO="1">
<TITLE MODIFIED="2008-06-17 14:08:56 +0100" MODIFIED_BY="Cathy Bennett">
<I>Search terms used to locate specific studies in the Cochrane Skin Group Specialised Register</I>
</TITLE>
<APPENDIX_BODY MODIFIED="2008-06-17 14:09:03 +0100" MODIFIED_BY="Cathy Bennett">
<P>(cicatricial and pemphigoid) or (mucous and membrane and pemphigoid) or (epidermol and bullosa and acquisita)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-06-17 14:10:31 +0100" MODIFIED_BY="Cathy Bennett" NO="2">
<TITLE MODIFIED="2008-06-17 14:10:31 +0100" MODIFIED_BY="Cathy Bennett">
<I>Search terms used to locate specific studies (CCTs and RCTs) on the Cochrane Library (CENTRAL)</I>
</TITLE>
<APPENDIX_BODY MODIFIED="2008-06-17 14:09:41 +0100" MODIFIED_BY="Cathy Bennett">
<P>(cicatricial and pemphigoid)<BR/>(mucous next membrane next pemphigoid)<BR/>(epidermol next bullosa next acquisita)<BR/>(#1 or #2 or #3)<BR/>(bullous next pemphigoid)<BR/>PEMPHIGOID BULLOUS<BR/>(gestationis near pemphigoid)<BR/>(#5 or #6 or #7)<BR/>(#4 and (not #8))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2008-06-17 14:16:42 +0100" MODIFIED_BY="Cathy Bennett" NO="3">
<TITLE MODIFIED="2008-06-17 14:16:42 +0100" MODIFIED_BY="Cathy Bennett">
<I>Search strategies to locate specific trials (CCTs and RCTs) in MEDLINE / PubMed (OVID)</I>
</TITLE>
<APPENDIX_BODY MODIFIED="2008-06-17 14:15:47 +0100" MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="3">Search lines 1-29, as given in the Cochrane Reviewers' Handbook (Alderson 2004) 5b2.</HEADING>
<P>30. Pemphigoid, Benign Mucous Membrane/<BR/>31. cicatricial pemphigoid.mp.<BR/>32. ocular pemphigoid.mp.<BR/>33. Epidermolysis Bullosa Acquisita/<BR/>34. 30 or 31 or 32 or 33<BR/>35. 29 and 34</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Search strategy to locate any intervention in Mucous membrane pemphigoid and Epidermolysis bullosa acquisita in PubMed</HEADING>
<P>#1<BR/>"Epidermolysis Bullosa Acquisita"[MeSH] OR "Pemphigoid, Benign Mucous Membrane"[MeSH] OR Epidermolysis Bullosa Acquisita[tw] OR Acquired Epidermolysis Bullosa[tw] OR Mucous Membrane Pemphigoid[tw] OR Cicatricial Pemphigoid[tw] OR epidermolysis bullosa acquisita[tw]<BR/>#2<BR/>therapy OR treatment OR medication OR predniso* OR corticosteroid* OR steroid* OR immunosupp* OR azathioprin* OR cyclophosphamid* OR methotrexat* OR chlorambucil* OR cyclosporin* OR antibiotic* OR dapson* OR sulpha* OR sulfa* OR sulfala* OR erythromycin* OR tetracyclin* OR minocin* OR minocyclin* OR nicotinamid* OR plasmaph* OR plasmaexchange* OR surgery OR surgical or immunoglob* OR mycophenolate OR mofetil or tacrolimus or adalimumab or alefacept or efalizumab or etanercept or infliximab or rituximab or anti-CD20 OR anti-TNF alpha OR anti-CD11a</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2008-06-17 14:11:20 +0100" MODIFIED_BY="Cathy Bennett" NO="4">
<TITLE MODIFIED="2008-06-17 14:11:16 +0100" MODIFIED_BY="Cathy Bennett">
<I>Search strategy to locate specific trials (CCTs and RCTs) in EMBASE</I>
</TITLE>
<APPENDIX_BODY MODIFIED="2008-06-17 14:11:20 +0100" MODIFIED_BY="Cathy Bennett">
<P>1. random$.mp.<BR/>2. factorial$.mp.<BR/>3. crossover$.mp.<BR/>4. placebo$.mp. or PLACEBO/<BR/>5. (doubl$ adj blind$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>6. (singl$ adj blind$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>7. assign$.mp.<BR/>8. volunteer$.mp. or VOLUNTEER/<BR/>9. Crossover Procedure/<BR/>10. Double Blind Procedure/<BR/>11. Randomized Controlled Trial/<BR/>12. Single Blind Procedure/<BR/>13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12<BR/>14. Cicatricial Pemphigoid/<BR/>15. ocular pemphigoid.mp.<BR/>16. mucous membrane pemphigoid.mp.<BR/>17. Epidermolysis Bullosa Acquisita/<BR/>18. 14 or 15 or 16 or 17<BR/>19. 13 and 18</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2008-06-17 14:17:03 +0100" MODIFIED_BY="Cathy Bennett" NO="5">
<TITLE MODIFIED="2008-06-17 14:17:03 +0100" MODIFIED_BY="Cathy Bennett">Search terms for www.controlled-trials.com (7th April 2005) and www.clinicaltrials.gov (7th April 2005)</TITLE>
<APPENDIX_BODY MODIFIED="2008-06-17 14:13:46 +0100" MODIFIED_BY="Cathy Bennett">
<P>pemphgoid<BR/>epidermolysis bullosa</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>